Author: "E. Colombo" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"E. Colombo"' showing total 1,184 results

Start Over Author "E. Colombo"

1,184 results on '"E. Colombo"'

1. Light-induced charge generation in polymeric nanoparticles restores vision in advanced-stage retinitis pigmentosa rats

Author: S. Francia, D. Shmal, S. Di Marco, G. Chiaravalli, J. F. Maya-Vetencourt, G. Mantero, C. Michetti, S. Cupini, G. Manfredi, M. L. DiFrancesco, A. Rocchi, S. Perotto, M. Attanasio, R. Sacco, S. Bisti, M. Mete, G. Pertile, G. Lanzani, E. Colombo, and F. Benfenati
Subjects: Science
Abstract: Retinal dystrophies such as Retinitis pigmentosa are among the most prevalent causes of inherited incurable legal blindness. Here the authors demonstrate that conjugated polymer nanoparticles reinstate visual functions in aged rats with fully degenerated and rewired retinas.
Published: 2022
Full Text: View/download PDF

2. Segmentation techniques of cerebral arteriovenous malformations for 3D visualisation: a systematic review

Author: E. Colombo, T. Fick, G. Esposito, M. Germans, L. Regli, and T. van Doormaal
Subjects: Neurology. Diseases of the nervous system, RC346-429
Published: 2022
Full Text: View/download PDF

3. Multimessenger Characterization of Markarian 501 during Historically Low X-Ray and γ-Ray Activity

Author: H. Abe, S. Abe, V. A. Acciari, I. Agudo, T. Aniello, S. Ansoldi, L. A. Antonelli, A. Arbet-Engels, C. Arcaro, M. Artero, K. Asano, D. Baack, A. Babić, A. Baquero, U. Barres de Almeida, J. A. Barrio, I. Batković, J. Baxter, J. Becerra González, W. Bednarek, E. Bernardini, M. Bernardos, A. Berti, J. Besenrieder, W. Bhattacharyya, C. Bigongiari, A. Biland, O. Blanch, G. Bonnoli, Ž. Bošnjak, I. Burelli, G. Busetto, R. Carosi, M. Carretero-Castrillo, A. J. Castro-Tirado, G. Ceribella, Y. Chai, A. Chilingarian, S. Cikota, E. Colombo, J. L. Contreras, J. Cortina, S. Covino, G. D’Amico, V. D’Elia, P. Da Vela, F. Dazzi, A. De Angelis, B. De Lotto, A. Del Popolo, M. Delfino, J. Delgado, C. Delgado Mendez, D. Depaoli, F. Di Pierro, L. Di Venere, E. Do Souto Espiñeira, D. Dominis Prester, A. Donini, D. Dorner, M. Doro, D. Elsaesser, G. Emery, J. Escudero, V. Fallah Ramazani, L. Fariña, A. Fattorini, L. Foffano, L. Font, C. Fruck, S. Fukami, Y. Fukazawa, R. J. García López, M. Garczarczyk, S. Gasparyan, M. Gaug, J. G. Giesbrecht Paiva, N. Giglietto, F. Giordano, P. Gliwny, N. Godinović, R. Grau, D. Green, J. G. Green, D. Hadasch, A. Hahn, T. Hassan, L. Heckmann, J. Herrera, D. Hrupec, M. Hütten, R. Imazawa, T. Inada, R. Iotov, K. Ishio, I. Jiménez Martínez, J. Jormanainen, D. Kerszberg, Y. Kobayashi, H. Kubo, J. Kushida, A. Lamastra, D. Lelas, F. Leone, E. Lindfors, L. Linhoff, S. Lombardi, F. Longo, R. López-Coto, M. López-Moya, A. López-Oramas, S. Loporchio, A. Lorini, E. Lyard, B. Machado de Oliveira Fraga, P. Majumdar, M. Makariev, G. Maneva, N. Mang, M. Manganaro, S. Mangano, K. Mannheim, M. Mariotti, M. Martínez, A. Mas-Aguilar, D. Mazin, S. Menchiari, S. Mender, S. Mićanović, D. Miceli, T. Miener, J. M. Miranda, R. Mirzoyan, E. Molina, H. A. Mondal, A. Moralejo, D. Morcuende, V. Moreno, T. Nakamori, C. Nanci, L. Nava, V. Neustroev, M. Nievas Rosillo, C. Nigro, K. Nilsson, K. Nishijima, T. Njoh Ekoume, K. Noda, S. Nozaki, Y. Ohtani, T. Oka, A. Okumura, J. Otero-Santos, S. Paiano, M. Palatiello, D. Paneque, R. Paoletti, J. M. Paredes, L. Pavletić, M. Persic, M. Pihet, G. Pirola, F. Podobnik, P. G. Prada Moroni, E. Prandini, G. Principe, C. Priyadarshi, W. Rhode, M. Ribó, J. Rico, C. Righi, A. Rugliancich, N. Sahakyan, T. Saito, S. Sakurai, K. Satalecka, F. G. Saturni, B. Schleicher, K. Schmidt, F. Schmuckermaier, J. L. Schubert, T. Schweizer, J. Sitarek, V. Sliusar, D. Sobczynska, A. Spolon, A. Stamerra, J. Strišković, D. Strom, M. Strzys, Y. Suda, T. Surić, H. Tajima, M. Takahashi, R. Takeishi, F. Tavecchio, P. Temnikov, K. Terauchi, T. Terzić, M. Teshima, L. Tosti, S. Truzzi, A. Tutone, S. Ubach, J. van Scherpenberg, M. Vazquez Acosta, S. Ventura, V. Verguilov, I. Viale, C. F. Vigorito, V. Vitale, I. Vovk, R. Walter, M. Will, C. Wunderlich, T. Yamamoto, D. Zarić, The MAGIC Collaboration, M. Cerruti, J. A. Acosta-Pulido, G. Apolonio, R. Bachev, M. Baloković, E. Benítez, I. Björklund, V. Bozhilov, L. F. Brown, A. Bugg, W. Carbonell, M. I. Carnerero, D. Carosati, C. Casadio, W. Chamani, W. P. Chen, R. A. Chigladze, G. Damljanovic, K. Epps, A. Erkenov, M. Feige, J. Finke, A. Fuentes, K. Gazeas, M. Giroletti, T. S. Grishina, A. C. Gupta, M. A. Gurwell,, E. Heidemann, D. Hiriart, W. J. Hou, T. Hovatta, S. Ibryamov, M. D. Joner, S. G. Jorstad, J. Kania, S. Kiehlmann, G. N. Kimeridze, E. N. Kopatskaya, M. Kopp, M. Korte, B. Kotas, S. Koyama, J. A. Kramer, L. Kunkel, S. O. Kurtanidze, O. M. Kurtanidze, A. Lähteenmäki, J. M. López, V. M. Larionov, E. G. Larionova, L. V. Larionova, C. Leto, C. Lorey, R. Mújica, G. M. Madejski, N. Marchili, A. P. Marscher, M. Minev, A. Modaressi, D. A. Morozova, T. Mufakharov, I. Myserlis, A. A. Nikiforova, M. G. Nikolashvili, E. Ovcharov, M. Perri, C. M. Raiteri, A. C. S. Readhead, A. Reimer, D. Reinhart, S. Righini, K. Rosenlehner, A. C. Sadun, S. S. Savchenko, A. Scherbantin, L. Schneider, K. Schoch, D. Seifert, E. Semkov, L. A. Sigua, C. Singh, P. Sola, Y. Sotnikova, M. Spencer, R. Steineke, M. Stojanovic, A. Strigachev, M. Tornikoski, E. Traianou, A. Tramacere, Yu. V. Troitskaya, I. S. Troitskiy, J. B. Trump, A. Tsai, A. Valcheva, A. A. Vasilyev, F. Verrecchia, M. Villata, O. Vince, K. Vrontaki, Z. R. Weaver, E. Zaharieva, and N. Zottmann
Subjects: Active galaxies, BL Lacertae objects, Markarian galaxies, Active galactic nuclei, Blazars, Astrophysics, QB460-466
Abstract: We study the broadband emission of Mrk 501 using multiwavelength observations from 2017 to 2020 performed with a multitude of instruments, involving, among others, MAGIC, Fermi's Large Area Telescope (LAT), NuSTAR, Swift, GASP-WEBT, and the Owens Valley Radio Observatory. Mrk 501 showed an extremely low broadband activity, which may help to unravel its baseline emission. Nonetheless, significant flux variations are detected at all wave bands, with the highest occurring at X-rays and very-high-energy (VHE) γ -rays. A significant correlation (>3 σ ) between X-rays and VHE γ -rays is measured, supporting leptonic scenarios to explain the variable parts of the emission, also during low activity. This is further supported when we extend our data from 2008 to 2020, and identify, for the first time, significant correlations between the Swift X-Ray Telescope and Fermi-LAT. We additionally find correlations between high-energy γ -rays and radio, with the radio lagging by more than 100 days, placing the γ -ray emission zone upstream of the radio-bright regions in the jet. Furthermore, Mrk 501 showed a historically low activity in X-rays and VHE γ -rays from mid-2017 to mid-2019 with a stable VHE flux (>0.2 TeV) of 5% the emission of the Crab Nebula. The broadband spectral energy distribution (SED) of this 2 yr long low state, the potential baseline emission of Mrk 501, can be characterized with one-zone leptonic models, and with (lepto)-hadronic models fulfilling neutrino flux constraints from IceCube. We explore the time evolution of the SED toward the low state, revealing that the stable baseline emission may be ascribed to a standing shock, and the variable emission to an additional expanding or traveling shock.
Published: 2023
Full Text: View/download PDF

4. Diagnostic Accuracy of Anticarbamylated Protein Antibodies in Established Rheumatoid Arthritis: A Monocentric Cross‐Sectional Study

Author: G. L. Erre, N. Mundula, E. Colombo, A. A. Mangoni, L. A. Sechi, M. Oggiano, R. Irde, A. Zinellu, G. Passiu, and C. Carru
Subjects: Diseases of the musculoskeletal system, RC925-935
Abstract: Objective To evaluate the diagnostic accuracy of anticarbamylated protein antibodies (CarP), alone and in combination with traditional biomarkers (rheumatoid factor [RF] and anticitrullinated peptide antibodies [ACPA]), in established rheumatoid arthritis (RA). Methods A commercially available enzyme‐linked immunosorbent assay (ELISA) kit was used to assess CarP concentrations in serum samples of 200 established RA and 206 controls (115 healthy donors and 55 patients with other rheumatic diseases). Main outcome measures were sensitivity, specificity, and area under the curve (AUC; 95% confidence interval [CI]). Difference in accuracy was evaluated by comparison of the respective AUCs. Results A serum CarP cut‐off of 1.47 ng/ml or more differentiated patients with RA from controls with 30% sensitivity, 97.1% specificity, and good accuracy (AUC[95%CI] = 0.83[0.79‐0.86], P < 0.0001). However, it showed moderate diagnostic accuracy in seronegative RA patients: sensitivity 17.9%, specificity 96.9%, and AUC (95% CI) = 0.69 (0.63‐0.75). The diagnostic accuracy of CarP_ACPA and CarP_RF combinations was significantly superior to that of ACPA and RF alone (P < 0.0001 and P = 0.015, respectively), but not to that of ACPA_RF combination (P = 0.089) In addition, the CarP_ACPA_RF combination did not improve the diagnostic accuracy of the ACPA_RF combination (AUC mean difference [95% CI] = 0.006 [−0.001 to 0.015], P = 0.10). The number of positive autoantibodies (0, 1, 2, or 3) was not significantly associated with moderate‐severe disease (Disease Activity Score‐28 [DAS‐28] > 3.2) in adjusted multiple regression analysis. Conclusion CarP has good diagnostic accuracy in established RA but not in seronegative RA. The addition of CarP to ACPA and RF alone or in combination does not significantly enhance the diagnostic accuracy of ACPA_RF combination.
Published: 2019
Full Text: View/download PDF

5. Confort visual en oficinas, factor temporal en la evaluación de deslumbramiento

Author: J. Yamin, A. Pattini, and E. Colombo
Subjects: iluminación natural, deslumbramiento, trabajo de oficinas, confort visual, Architecture, NA1-9428, Building construction, TH1-9745
Abstract: Para lograr los beneficios de iluminar con luz natural espacios de trabajo, hay que evitar que la luz natural sea bloqueada por el potencial riesgo de deslumbramiento. Para lograr una adecuada caracterización del mismo es importante considerar la percepción del tiempo de exposición de la fuente en el campo de visión (Aspecto no incluido en los modelos de deslumbramiento). Para determinar de qué manera influye este aspecto perceptual en la sensación de deslumbramiento se evaluaron dos escenarios con dos tipos de manchas solares sobre el puesto de trabajo: 1) Con mayor profundidad de ingreso y más tiempo en el campo de visión, 2) Con menor profundidad de ingreso y menos tiempo en el campo de visión. Se midieron parámetros subjetivos (GSV) y variables fotométricas (DGP, EV y CL). Siendo la principal variable explicativa la EV (rho=0.51). Observándose también una mayor tolerancia al deslumbramiento por el efecto transitorio de la fuente.
Published: 2020
Full Text: View/download PDF

6. ESICM LIVES 2016: part one

Author: L. Bos, L. Schouten, L. van Vught, M. Wiewel, D. Ong, O. Cremer, A. Artigas, I. Martin-Loeches, A. Hoogendijk, T. van der Poll, J. Horn, N. Juffermans, M. Schultz, N. de Prost, T. Pham, G. Carteaux, A. Mekontso Dessap, C. Brun-Buisson, E. Fan, G. Bellani, J. Laffey, A. Mercat, L. Brochard, B. Maitre, LUNG SAFE investigators and the ESICM study group, P. A. Howells, D. R. Thickett, C. Knox, D. P. Park, F. Gao, O. Tucker, T. Whitehouse, D. F. McAuley, G. D. Perkins, LUNG SAFE Investigators and the ESICM Trials Group, L. Pisani, J. P. Roozeman, F. D. Simonis, A. Giangregorio, L. R. Schouten, S. M. Van der Hoeven, A. Serpa Neto, E. Festic, A. M. Dondorp, S. Grasso, L. D. Bos, M. J. Schultz, M. Koster-Brouwer, D. Verboom, B. Scicluna, K. van de Groep, J. Frencken, M. Bonten, J. I. Ko, K. S. Kim, G. J. Suh, W. Y. Kwon, K. Kim, J. H. Shin, O. T. Ranzani, E. Prina, R. Menendez, A. Ceccato, R. Mendez, C. Cilloniz, A. Gabarrus, M. Ferrer, A. Torres, A. Urbano, L. A. Zhang, D. Swigon, F. Pike, R. S. Parker, G. Clermont, C. Scheer, S. O. Kuhn, A. Modler, M. Vollmer, C. Fuchs, K. Hahnenkamp, S. Rehberg, M. Gründling, A. Taggu, N. Darang, N. Öveges, I. László, K. Tánczos, M. Németh, G. Lebák, B. Tudor, D. Érces, J. Kaszaki, W. Huber, D. Trásy, Z. Molnár, G. Ferrara, V. S. Kanoore Edul, H. S. Canales, E. Martins, C. Canullán, G. Murias, M. O. Pozo, J. F. Caminos Eguillor, M. G. Buscetti, C. Ince, A. Dubin, H. D. Aya, A. Rhodes, N. Fletcher, R. M. Grounds, M. Cecconi, M. Jacquet-Lagrèze, M. Riche, R. Schweizer, P. Portran, W. Fornier, M. Lilot, J. Neidecker, J. L. Fellahi, A. Escoresca-Ortega, A. Gutiérrez-Pizarraya, L. Charris-Castro, Y. Corcia-Palomo, E. Fernandez-Delgado, J. Garnacho-Montero, C. Roger, L. Muller, L. Elotmani, J. Lipman, J. Y. Lefrant, J. A. Roberts, R. Muñoz-Bermúdez, M. Samper, C. Climent, F. Vasco, V. Sara, S. Luque, N. Campillo, S. Grau Cerrato, J. R. Masclans, F. Alvarez-Lerma, S. Carvalho Brugger, G. Jimenez Jimenez, M. Miralbés Torner, J. Trujillano Cabello, B. Balsera Garrido, X. Nuvials Casals, F. Barcenilla Gaite, M. Vallverdú Vidal, M. Palomar Martínez, V. Gusarov, D. Shilkin, M. Dementienko, E. Nesterova, N. Lashenkova, A. Kuzovlev, M. Zamyatin, A. Demoule, S. Carreira, S. Lavault, O. Palancca, E. Morawiec, J. Mayaux, I. Arnulf, T. Similowski, B. S. Rasmussen, R. G. Maltesen, M. Hanifa, S. Pedersen, S. R. Kristensen, R. Wimmer, M. Panigada, G. Li Bassi, T. Kolobow, A. Zanella, M. Cressoni, L. Berra, V. Parrini, H. Kandil, G. Salati, S. Livigni, A. Amatu, A. Andreotti, F. Tagliaferri, G. Moise, G. Mercurio, A. Costa, A. Vezzani, S. Lindau, J. Babel, M. Cavana, D. Consonni, A. Pesenti, L. Gattinoni, for the GRAVITY-VAP TRIAL NETWORK, P. Mansouri, F. Zand, L. Zahed, F. Dehghanrad, M. Bahrani, M. Ghorbani, B. Cambiaghi, O. Moerer, T. Mauri, N. Kunze-Szikszay, C. Ritter, M. Quintel, L. M. Vilander, M. A. Kaunisto, S. T. Vaara, V. Pettilä, FINNAKI Study Group, J. L. G. Haitsma Mulier, S. Rozemeijer, A. M. E. Spoelstra-de Man, P. E. Elbers, P. R. Tuinman, M. C. de Waard, H. M. Oudemans-van Straaten, A. M. A. Liberatore, R. B. Souza, A. M. C. R. P. F. Martins, J. C. F. Vieira, I. H. J. Koh, M. Galindo Martínez, R. Jiménez Sánchez, L. Martínez Gascón, M. D. Rodríguez Mulero, A. Ortín Freire, A. Ojados Muñoz, S. Rebollo Acebes, Á. Fernández Martínez, S. Moreno Aliaga, L. Herrera Para, J. Murcia Payá, F. Rodríguez Mulero, P. Guerci, Y. Ince, P. Heeman, B. Ergin, Z. Uz, M. Massey, R. Papatella, E. Bulent, F. Toraman, E. R. Longbottom, H. D. Torrance, H. C. Owen, C. J. Hinds, R. M. Pearse, M. J. O’Dywer, Z. Trogrlic, M. van der Jagt, H. Lingsma, H. H. Ponssen, J. F. Schoonderbeek, F. Schreiner, S. J. Verbrugge, S. Duran, T. van Achterberg, J. Bakker, D. A. M. P. J. Gommers, E. Ista, A. Krajčová, P. Waldauf, F. Duška, A. Shah, N. Roy, S. McKechnie, C. Doree, S. Fisher, S. J. Stanworth, J. F. Jensen, D. Overgaard, M. H. Bestle, D. F. Christensen, I. Egerod, The RAPIT Group, A. Pivkina, I. Zhivotneva, N. Pasko, A. Alklit, R. L. Hansen, H. Knudsen, L. B. Grode, The RAPIT group, M. Hravnak, L. Chen, A. Dubrawski, M. R. Pinsky, S. M. Parry, L. D. Knight, B. C. Connolly, C. E. Baldwin, Z. A. Puthucheary, L. Denehy, N. Hart, P. E. Morris, J. Mortimore, C. L. Granger, H. I. Jensen, R. Piers, B. Van den Bulcke, J. Malmgren, V. Metaxa, A. K. Reyners, M. Darmon, K. Rusinova, D. Talmor, A. P. Meert, L. Cancelliere, L. Zubek, P. Maia, A. Michalsen, J. Decruyenaere, E. Kompanje, S. Vanheule, E. Azoulay, S. Vansteelandt, D. Benoit, C. Ryan, D. Dawson, J. Ball, K. Noone, B. Aisling, S. Prudden, A. Ntantana, D. Matamis, S. Savvidou, M. Giannakou, M. Gouva, G. Nakos, V. Koulouras, J. Aron, G. Lumley, D. Milliken, K. Dhadwal, B. A. McGrath, S. J. Lynch, B. Bovento, G. Sharpe, E. Grainger, S. Pieri-Davies, S. Wallace, B. McGrath, M. Jung, J. Cho, H. Park, G. Suh, O. Kousha, J. Paddle, L. Gamrin Gripenberg, M. Sundström Rehal, J. Wernerman, O. Rooyackers, H. J. de Grooth, W. P. Choo, A. M. Spoelstra-de Man, E. L. Swart, L. Talan, G. Güven, N. D. Altıntas, M. Padar, G. Uusvel, L. Starkopf, J. Starkopf, A. Reintam Blaser, M. S. Kalaiselvan, A. S. Arunkumar, M. K. Renuka, R. L. Shivkumar, M. Volbeda, D. ten Kate, M. Hoekstra, J. M. van der Maaten, M. W. Nijsten, A. Komaromi, Å. Norberg, M. Smedberg, M. Mori, L. Pettersson, M. Theodorakopoulou, T. Christodoulopoulou, A. Diamantakis, F. Frantzeskaki, M. Kontogiorgi, E. Chrysanthopoulou, M. Lygnos, C. Diakaki, A. Armaganidis, K. Gundogan, E. Dogan, R. Coskun, S. Muhtaroglu, M. Sungur, T. Ziegler, M. Guven, A. Kleyman, W. Khaliq, D. Andreas, M. Singer, R. Meierhans, R. Schuepbach, I. De Brito-Ashurst, G. Sabetian, R. Nikandish, F. Hagar, M. Masjedi, B. Maghsudi, A. Vazin, E. Asadpour, K. C. Kao, L. C. Chiu, C. Y. Hung, C. H. Chang, S. H. Li, H. C. Hu, S. El Maraghi, M. Ali, D. Rageb, M. Helmy, J. Marin-Corral, C. Vilà, A. Vàzquez, I. Martín-Loeches, E. Díaz, J. C. Yébenes, A. Rodriguez, F. Álvarez-Lerma, H1N1 SEMICYUC/GETGAG Working Group, N. Varga, A. Cortina-Gutiérrez, L. Dono, M. Martínez-Martínez, C. Maldonado, E. Papiol, M. Pérez-Carrasco, R. Ferrer, K. Nweze, B. Morton, I. Welters, M. Houard, B. Voisin, G. Ledoux, S. Six, E. Jaillette, S. Nseir, S. Romdhani, R. Bouneb, D. Loghmari, N. Ben Aicha, J. Ayachi, K. Meddeb, I. Chouchène, A. Khedher, M. Boussarsar, K. S. Chan, W. L. Yu, J. Nolla, L. Vidaur, J. Bonastre, B. Suberbiola, J. E. Guerrero, H1N1 SEMICYUC/GETGAG working group, N. Ramon Coll, G. Jiménez Jiménez, J. Codina Calero, M. García, M. C. de la Torre, E. Vendrell, E. Palomera, E. Güell, M. Serra-Prat, J. F. Bermejo-Martín, J. Almirall, E. Tomas, A. Escoval, F. Froe, M. H. Vitoria Pereira, N. Velez, E. Viegas, E. Filipe, C. Groves, M. Reay, A. Ballin, F. Facchin, G. Sartori, F. Zarantonello, E. Campello, C. M. Radu, S. Rossi, C. Ori, P. Simioni, N. Umei, I. Shingo, A. C. Santos, C. Candeias, I. Moniz, R. Marçal, Z. Costa e Silva, J. M. Ribeiro, J. F. Georger, J. P. Ponthus, M. Tchir, V. Amilien, M. Ayoub, E. Barsam, G. Martucci, G. Panarello, F. Tuzzolino, G. Capitanio, V. Ferrazza, T. Carollo, L. Giovanni, A. Arcadipane, M. López Sánchez, M. A. González-Gay, F. J. Llorca Díaz, M. I. Rubio López, E. Zogheib, L. Villeret, J. Nader, M. Bernasinski, P. Besserve, T. Caus, H. Dupont, P. Morimont, S. Habran, R. Hubert, T. Desaive, F. Blaffart, N. Janssen, J. Guiot, A. Pironet, P. Dauby, B. Lambermont, T. Pettenuzzo, G. Citton, C. Kirakli, O. Ediboglu, S. Ataman, M. Yarici, F. Tuksavul, S. Keating, A. Gibson, M. Gilles, M. Dunn, G. Price, N. Young, P. Remeta, P. Bishop, M. D. Fernández Zamora, J. Muñoz-Bono, E. Curiel-Balsera, E. Aguilar-Alonso, R. Hinojosa, A. Gordillo-Brenes, J. A. Arboleda-Sánchez, ARIAM-CARDIAC SURGERY PROJECT AUTHORS, I. Skorniakov, D. Vikulova, C. Whiteley, O. Shaikh, A. Jones, M. Ostermann, L. Forni, M. Scott, J. Sahatjian, W. Linde-Zwirble, D. Hansell, P. Laoveeravat, N. Srisawat, M. Kongwibulwut, S. Peerapornrattana, N. Suwachittanont, T. O. Wirotwan, P. Chatkaew, P. Saeyub, K. Latthaprecha, K. Tiranathanagul, S. Eiam-ong, J. A. Kellum, R. E. Berthelsen, A. Perner, A. E. K. Jensen, J. U. Jensen, D. J. Gebhard, J. Price, C. E. Kennedy, A. Akcan-Arikan, Y. R. Kang, M. N. Nakamae, K. Hamed, M. M. Khaled, R. Aly Soliman, M. Sherif Mokhtar, G. Seller-Pérez, D. Arias-Verdú, E. Llopar-Valdor, I. De-Diós-Chacón, G. Quesada-García, M. E. Herrera-Gutierrez, R. Hafes, G. Carroll, P. Doherty, C. Wright, I. G. Guerra Vera, M. Ralston, M. L. Gemmell, A. MacKay, E. Black, R. I. Docking, R. Appleton, M. R. Ralston, L. Gemmell, A. Mackay, J. G. Röttgering, P. W. G. Elbers, N. Mejeni, J. Nsiala, A. Kilembe, P. Akilimali, G. Thomas, A. E. Andersson, A. M. Fagerdahl, V. Knudsen, P-INFECT, A. Ben Cheikh, Y. Hamdaoui, A. Guiga, N. Fraj, N. Sma, I. Chouchene, N. Bouafia, A. Amirian, B. Ziaian, C. Fleischmann, D. O. Thomas-Rueddel, A. Schettler, D. Schwarzkopf, A. Stacke, K. Reinhart, A. Martins, P. Sousa, G. Snell, R. Matsa, T. T. S. Paary, A. M. Cavalheiro, L. L. Rocha, C. S. Vallone, A. Tonilo, M. D. S. Lobato, D. T. Malheiro, G. Sussumo, N. M. Lucino, V. D. Rosenthal, A. Sanaei Dashti, A. Yousefipour, J. R. Goodall, M. Williamson, E. Tant, N. Thomas, C. Balci, C. Gonen, E. Haftacı, H. Gurarda, E. Karaca, B. Paldusová, I. Zýková, D. Šímová, S. Houston, L. D’Antona, J. Lloyd, V. Garnelo-Rey, M. Sosic, V. Sotosek-Tokmazic, J. Kuharic, I. Antoncic, S. Dunatov, A. Sustic, C. T. Chong, M. Sim, T. Lyovarin, F. M. Acosta Díaz, S. Narbona Galdó, M. Muñoz Garach, O. Moreno Romero, A. M. Pérez Bailón, A. Carranza Pinel, M. Colmenero, A. Gritsan, A. Gazenkampf, E. Korchagin, N. Dovbish, R. M. Lee, M. P. P. Lim, B. C. L. Lim, J. J. See, R. Assis, F. Filipe, N. Lopes, L. Pessoa, T. Pereira, N. Catorze, M. S. Aydogan, C. Aldasoro, P. Marchio, A. Jorda, M. D. Mauricio, S. Guerra-Ojeda, M. Gimeno-Raga, M. Colque-Cano, A. Bertomeu-Artecero, M. Aldasoro, S. L. Valles, D. Tonon, T. Triglia, J. C. Martin, M. C. Alessi, N. Bruder, P. Garrigue, L. Velly, S. Spina, V. Scaravilli, C. Marzorati, E. Colombo, D. Savo, A. Vargiolu, G. Cavenaghi, G. Citerio, A. H. V. Andrade, P. Bulgarelli, J. A. P. Araujo, V. Gonzalez, V. A. Souza, C. Massant, C. A. C. Abreu Filho, R. A. Morbeck, L. E. Burgo, R. van Groenendael, L. T. van Eijk, G. P. Leijte, B. Koeneman, M. Kox, P. Pickkers, A. García-de la Torre, M. de la Torre-Prados, A. Fernández-Porcel, C. Rueda-Molina, P. Nuevo-Ortega, T. Tsvetanova-Spasova, E. Cámara-Sola, A. García-Alcántara, L. Salido-Díaz, X. Liao, T. Feng, J. Zhang, X. Cao, Q. Wu, Z. Xie, H. Li, Y. Kang, M. S. Winkler, A. Nierhaus, E. Mudersbach, A. Bauer, L. Robbe, C. Zahrte, E. Schwedhelm, S. Kluge, C. Zöllner, E. Mitsi, S. H. Pennington, J. Reine, A. D. Wright, R. Parker, I. D. Welters, J. D. Blakey, G. Rajam, E. W. Ades, D. M. Ferreira, D. Wang, A. Kadioglu, S. B. Gordon, R. Koch, J. Rahamat-Langedoen, J. Schloesser, M. de Jonge, J. Bringue, R. Guillamat-Prats, E. Torrents, M. L. Martinez, M. Camprubí-Rimblas, L. Blanch, S. Y. Park, Y. B. Park, D. K. Song, S. Shrestha, S. H. Park, Y. Koh, M. J. Park, C. W. Hong, O. Lesur, D. Coquerel, X. Sainsily, J. Cote, T. Söllradl, A. Murza, L. Dumont, R. Dumaine, M. Grandbois, P. Sarret, E. Marsault, D. Salvail, M. Auger-Messier, F. Chagnon, Apelin Group, M. P. Lauretta, E. Greco, A. Dyson, S. Preau, M. Ambler, A. Sigurta, S. Saeed, L. Topcu Sarıca, N. Zibandeh, D. Genc, F. Gul, T. Akkoc, E. Kombak, L. Cinel, I. Cinel, S. J. Pollen, N. Arulkumaran, G. Warnes, D. J. Pennington, K. Brohi, M. J. O’Dwyer, H. Y. Kim, S. Na, J. Kim, Y. F. Chang, A. Chao, P. Y. Shih, C. T. Lee, Y. C. Yeh, L. W. Chen, M. Adriaanse, W. Rietdijk, S. Funcke, S. Sauerlaender, B. Saugel, H. Pinnschmidt, D. A. Reuter, R. Nitzschke, S. Perbet, C. Biboulet, A. Lenoire, D. Bourdeaux, B. Pereira, B. Plaud, J. E. Bazin, V. Sautou, A. Mebazaa, J. M. Constantin, M. Legrand, Y. Boyko, P. Jennum, M. Nikolic, H. Oerding, R. Holst, P. Toft, H. K. Nedergaard, T. Haberlandt, S. Park, S. Kim, Y. J. Cho, Y. J. Lim, A. Chan, S. Tang, S. L. Nunes, S. Forsberg, H. Blomqvist, L. Berggren, M. Sörberg, T. Sarapohja, C. J. Wickerts, J. G. M. Hofhuis, L. Rose, B. Blackwood, E. Akerman, J. Mcgaughey, M. Fossum, H. Foss, E. Georgiou, H. J. Graff, M. Kalafati, R. Sperlinga, A. Schafer, A. G. Wojnicka, P. E. Spronk, F. Khalili, R. Afshari, H. Haddad Khodaei, S. Javadpour, P. Petramfar, S. Nasimi, H. Tabei, A. Gunther, J. O. Hansen, P. Sackey, H. Storm, J. Bernhardsson, Ø. Sundin, A. Bjärtå, A. Bienert, P. Smuszkiewicz, P. Wiczling, K. Przybylowski, A. Borsuk, I. Trojanowska, J. Matysiak, Z. Kokot, M. Paterska, E. Grzeskowiak, A. Messina, E. Bonicolini, D. Colombo, G. Moro, S. Romagnoli, A. R. De Gaudio, F. Della Corte, S. M. Romano, J. A. Silversides, E. Major, E. E. Mann, A. J. Ferguson, D. F. Mcauley, J. C. Marshall, J. A. Diaz-Rodriguez, R. Silva-Medina, E. Gomez-Sandoval, N. Gomez-Gonzalez, R. Soriano-Orozco, P. L. Gonzalez-Carrillo, M. Hernández-Flores, K. Pilarczyk, J. Lubarksi, D. Wendt, F. Dusse, J. Günter, B. Huschens, E. Demircioglu, H. Jakob, A. Palmaccio, A. M. Dell’Anna, D. L. Grieco, F. Torrini, C. Iaquaniello, F. Bongiovanni, M. Antonelli, L. Toscani, D. Antonakaki, D. Bastoni, M. Jozwiak, F. Depret, J. L. Teboul, J. Alphonsine, C. Lai, C. Richard, X. Monnet, G. Demeter, I. Kertmegi, A. Hasanin, A. Lotfy, A. El-adawy, H. Nassar, S. Mahmoud, A. Abougabal, A. Mukhtar, F. Quinty, S. Habchi, A. Luzi, E. Antok, G. Hernandez, B. Lara, L. Enberg, M. Ortega, P. Leon, C. Kripper, P. Aguilera, E. Kattan, M. Lehmann, S. Sakka, B. Bein, R. M. Schmid, J. Preti, J. Creteur, A. Herpain, J. Marc, F. Trojette, S. Bar, L. Kontar, D. Titeca, J. Richecoeur, B. Gelee, N. Verrier, R. Mercier, E. Lorne, J. Maizel, M. Slama, M. E. Abdelfattah, A. Eladawy, M. A. Ali Elsayed, A. Pedraza Montenegro, E. Monares Zepeda, J. Franco Granillo, J. S. Aguirre Sánchez, G. Camarena Alejo, A. Rugerio Cabrera, A. A. Tanaka Montoya, C. Lee, F. Hatib, M. Cannesson, P. Theerawit, T. Morasert, Y. Sutherasan, G. Zani, S. Mescolini, M. Diamanti, R. Righetti, A. Scaramuzza, M. Papetti, M. Terenzoni, C. Gecele, M. Fusari, K. A. Hakim, A. Chaari, M. Ismail, A. H. Elsaka, T. M. Mahmoud, K. Bousselmi, V. Kauts, W. F. Casey, S. D. Hutchings, D. Naumann, J. Wendon, S. Watts, E. Kirkman, Z. Jian, S. Buddi, J. Settels, P. Bertini, F. Guarracino, C. Trepte, P. Richter, S. A. Haas, V. Eichhorn, J. C. Kubitz, M. S. Soliman, W. I. Hamimy, A. Z. Fouad, A. M. Mukhtar, M. Charlton, L. Tonks, L. Mclelland, T. J. Coats, J. P. Thompson, M. R. Sims, D. Williams, D. Z. Roushdy, R. A. Soliman, R. A. Nahas, M. Y. Arafa, W. T. Hung, C. C. Chiang, W. C. Huang, K. C. Lin, S. C. Lin, C. C. Cheng, P. L. Kang, S. R. Wann, G. Y. Mar, C. P. Liu, M. Lopez Carranza, H. Sancho Fernandez, J. A. Sanchez Roman, F. Lucena, A. Campanario Garcia, A. Loza Vazquez, A. Lesmes Serrano, ARIAM-SEMICYUC Registry Investigators, L. Sayagues Moreira, R. Vidal-Perez, U. Anido Herranz, J. M. Garcia Acuna, C. Pena Gil, J. L. Garcia Allut, P. Rascado Sedes, C. Martin Lopez, E. Saborido Paz, C. Galban Rodriguez, J. R. Gonzalez-Juanatey, A. Vallejo-Baez, M. V. de la Torre-Prados, ARIAM Group, R. Marharaj, K. Gervasio, M. Bottiroli, M. Mondino, D. De Caria, A. Calini, E. Montrasio, F. Milazzo, M. P. Gagliardone, A. Vallejo-Báez, ARIAM group, U. Anido, M. Cheikh-Bouhlel, M. P. R. D. L. Dela Cruz, J. M. Bernardo, F. Galfo, A. Marino, C. C. Chao, P. Hou, C. C. Hung, C. H. Chiang, Y. J. Liou, S. M. Hung, Y. S. Lin, F. Y. Kuo, K. R. Chiou, C. J. Chen, L. S. Yan, C. Y. Liu, H. H. Wang, H. L. Chen, C. K. Ho, S. Grewal, S. Gopal, C. Corbett, A. Wilson, J. Capps, W. Ayoub, A. Lomas, S. Ghani, J. Moore, D. Atkinson, M. Sharman, W. Swinnen, J. Pauwels, K. Mignolet, E. Pannier, A. Koch, T. Sarens, W. Temmerman, A. M. Elmenshawy, A. M. Fayed, M. Elboriuny, E. Hamdy, E. Zakaria, A. C. Falk, A. Petosic, K. Olafsen, H. Wøien, H. Flaatten, K. Sunde, J. J. Cáceres Agra, J. L. Santana Cabrera, J. D. Martín Santana, L. Melián Alzola, H. Rodríguez Pérez, T. Castro Pires, H. Calderón, A. Pereira, S. Castro, C. Granja, I. Norkiene, I. Urbanaviciute, G. Kezyte, D. Ringaitiene, T. Jovaisa, G. Vogel, U. B. Johansson, A. Sandgren, C. Svensen, E. Joelsson-Alm, M. A. Leite, L. D. Murbach, E. F. Osaku, C. R. L. M. Costa, M. Pelenz, N. M. Neitzke, M. M. Moraes, J. L. Jaskowiak, M. M. M. Silva, R. S. Zaponi, L. R. L. Abentroth, S. M. Ogasawara, A. C. Jorge, P. A. D. Duarte, J. Barreto, S. T. Duarte, S. Taba, D. Miglioranza, D. P. Gund, C. F. Lordani, H. Vollmer, M. Gager, C. Waldmann, A. T. Mazzeo, R. Tesio, C. Filippini, M. E. Vallero, C. Giolitti, S. Caccia, M. Medugno, T. Tenaglia, R. Rosato, I. Mastromauro, L. Brazzi, P. P. Terragni, R. Urbino, V. Fanelli, V. M. Ranieri, L. Mascia, J. Ballantyne, L. Paton, P. Perez-Teran, O. Roca, J. C. Ruiz-Rodriguez, A. Zapatero, J. Serra, S. Bianzina, P. Cornara, G. Rodi, G. Tavazzi, M. Pozzi, G. A. Iotti, F. Mojoli, A. Braschi, A. Vishnu, D. Buche, R. Pande, D. L. J. Moolenaar, F. Bakhshi-Raiez, D. A. Dongelmans, N. F. de Keizer, D. W. de Lange, I. Fuentes Fernández, D. Martínez Baño, J. L. Buendía Moreno, R. Jara Rubio, J. Scott, D. Phelan, D. Morely, J. O’Flynn, P. Stapleton, M. Lynch, B. Marsh, E. Carton, C. O’Loughlin, K. C. Cheng, M. I. Sung, M. O. Elghonemi, M. H. Saleh, T. S. Meyhoff, M. Krag, P. B. Hjortrup, M. H. Møller, T. Öhman, T. Sigmundsson, E. Redondo, M. Hallbäck, F. Suarez-Sipmann, H. Björne, C. Hällsjö Sander, KARISMA, D. Chiumello, C. Chiurazzi, M. Brioni, I. Algieri, M. Guanziroli, G. Vergani, T. Tonetti, I. Tomic, A. Colombo, F. Crimella, E. Carlesso, V. Gasparovic, R. El-Sherif, M. Abd Al-Basser, A. Raafat, A. El-Sherif, L. R. A. Schouten, O. L. Cremer, D. S. Y. Ong, G. Amoruso, G. Cinnella, L. D. J. Bos, P. Schmidle, M. Findeisen, P. Hoppmann, J. Jaitner, F. Brettner, T. Lahmer, EXODUS-investigators, G. Rajagopalan, V. Bansal, R. Frank, R. Hinds, J. Levitt, United States Critical Illness and Injury Trials Group/LIPS-B investigators, S. Siddiqui, SICM NICER Group, J. P. Gilbert, K. Sim, C. H. Wang, I. J. Li, W. R. Tang, P. Persona, A. De Cassai, M. Franco, A. Goffi, B. Llorente Ruiz, J. Lujan Varas, R. Molina Montero, C. Pintado Delgado, O. Navarrete, M. Vazquez Mezquita, E. Alonso Peces, M. A. M. Nakamura, L. A. Hajjar, F. R. B. G. Galas, T. A. Ortiz, M. B. P. Amato, L. Bitker, N. Costes, D. Le Bars, F. Lavenne, D. Mojgan, J. C. Richard, D. Massari, M. Gotti, P. Cadringher, A. Zerman, M. Türkoğlu, G. Arık, F. Yıldırım, Z. Güllü, I. Kara, N. Boyacı, B. Basarık Aydoğan, Ü. Gaygısız, K. Gönderen, G. Aygencel, M. Aydoğdu, Z. Ülger, G. Gürsel, J. Riera, C. Maldonado Toral, C. Mazo, M. Martínez, J. Baldirà, L. Lagunes, A. Roman, M. Deu, J. Rello, D. J. Levine, R. M. Mohus, Å. Askim, J. Paulsen, A. Mehl, A. T. Dewan, J. K. Damås, E. Solligård, B. O. Åsvold, Mid-Norway Sepsis Research Center, A. DeWan, O. Aktepe, A. Kara, H. Yeter, A. Topeli, M. Norrenberg, M. Devroey, H. Khader, J. C. Preiser, Z. Tang, C. Qiu, L. Tong, C. Cai, O. Apostolopoulou, J. Y. Moon, M. R. Park, I. S. Kwon, G. R. Chon, J. Y. Ahn, S. J. Kwon, Y. J. Chang, J. Y. Lee, S. Y. Yoon, J. W. Lee, The Korean Chungcheong Critical Care Research Group, M. Kostalas, J. Mckinlay, G. Kooner, G. Dudas, A. Horton, C. Kerr, N. Karanjia, B. Creagh-Brown, N. D. Altintas, S. Izdes, O. Keremoglu, A. Alkan, S. Neselioglu, O. Erel, N. Tardif, T. Gustafsson, K. N. MacEachern, M. Traille, I. Bromberg, S. E. Lapinsky, M. J. Moore, J. L. García-Garmendia, F. Villarrasa-Clemente, F. Maroto-Monserrat, O. Rufo-Tejeiro, V. Jorge-Amigo, M. Sánchez-Santamaría, C. Colón-Pallarés, A. Barrero-Almodóvar, S. Gallego-Lara, C. T. Anthon, R. B. Müller, N. Haase, K. Møller, J. Wetterslev, M. Nakanishi, A. Kuriyama, T. Fukuoka, M. A. Abd el Halim, M. H. Elsaid hafez, A. M. Moktar, H. M. Elazizy, K. Abdel Hakim, M. Elbahr, T. Mahmoud, E. Khalil, W. Casey, S. H. Zaky, A. Rizk, R. Ahmed, G. A. Ospina-Tascón, A. F. Garcia Marin, G. J. Echeverry, W. F. Bermudez, H. J. Madriñan-Navia, J. D. Valencia, E. Quiñonez, A. Marulanda, C. A. Arango-Dávila, A. Bruhn, D. De Backer, D. Orbegozo Cortes, F. Su, J. L. Vincent, L. Tullo, L. Mirabella, P. Di Molfetta, M. Dambrosio, C. Villavicencio Lujan, J. Leache irigoyen, M. Cartanya ferré, R. Carbonell García, M. Ahmed, M. El Ayashi, E. Ayman, M. Salem, S. Fathy, A. Zaghlol, M. F. Aguilar Arzapalo, Å. Valsø, T. Rustøen, I. Schou-Bredal, L. Skogstad, K. Tøien, C. Padilla, Y. Palmeiro, W. Egbaria, R. Kigli, B. Maertens, K. Blot, S. Blot, E. Santana-Santos, E. R. dos Santos, R. E. D. L. Ferretti-Rebustini, R. D. C. C. D. O. dos Santos, R. G. S. Verardino, L. A. Bortolotto, A. M. Doyle, I. Naldrett, J. Tillman, S. Price, P. Pearson, J. Greaves, D. Goodall, A. Berry, A. Richardson, G. O. Odundo, P. Omengo, P. Obonyo, N. M. Chanzu, R. Kleinpell, S. J. Sarris, P. Nedved, M. Heitschmidt, H. Ben-Ghezala, S. Snouda, S. Djobbi, N. K. J. Adhikari, D. Leasa, D. Fergusson, D. A. Mckim, J. Weblin, D. McWilliams, F. Doesburg, F. Cnossen, W. Dieperink, W. Bult, M. W. N. Nijsten, G. A. Galvez-Blanco, C. I. Olvera Guzman, J. Santos Stroud, R. Thomson, M. Llaurado-Serra, A. Lobo-Civico, M. Pi-Guerrero, I. Blanco-Sanchez, A. Piñol-Tena, C. Paños-Espinosa, Y. Alabart-Segura, B. Coloma-Gomez, A. Fernandez-Blanco, F. Braga-Dias, M. Treso-Geira, A. Valeiras-Valero, L. Martinez-Reyes, A. Sandiumenge, M. F. Jimenez-Herrera, CAPCRI Study, R. Prada, P. Juárez, R. Argandoña, J. J. Díaz, C. Sánchez Ramirez, P. Saavedra, S. Ruiz Santana, O. Obukhova, S. Kashiya, I. A. Kurmukov, A. M. Pronina, P. Simeone, L. Puybasset, G. Auzias, O. Coulon, B. Lesimple, G. Torkomian, A. Bartkowska-Sniatkowska, O. Szerkus, D. Siluk, J. Bartkowiak-Wieczorek, J. Rosada-Kurasinska, J. Warzybok, R. Kaliszan, C. Hernandez Caballero, S. Roberts, G. Isgro, D. Hall, G. Guillaume, O. Passouant, F. Dumas, W. Bougouin, B. Champigneulle, M. Arnaout, J. Chelly, J. D. Chiche, O. Varenne, J. P. Mira, E. Marijon, A. Cariou, M. Beerepoot, H. R. Touw, K. Parlevliet, C. Boer, P. W. Elbers, Á. J. Roldán Reina, Y. Corcia Palomo, R. Martín Bermúdez, L. Martín Villén, I. Palacios García, J. R. Naranjo Izurieta, J. B. Pérez Bernal, F. J. Jiménez Jiménez, Cardiac Arrest Group HUVR, F. Cota-Delgado, T. Kaneko, H. Tanaka, M. Kamikawa, R. Karashima, S. Iwashita, H. Irie, S. Kasaoka, O. Arola, R. Laitio, A. Saraste, J. Airaksinen, M. Pietilä, M. Hynninen, J. Wennervirta, M. Bäcklund, E. Ylikoski, P. Silvasti, E. Nukarinen, J. Grönlund, V. P. Harjola, J. Niiranen, K. Korpi, M. Varpula, R. O. Roine, T. Laitio, for the Xe-HYPOTHECA study group, S. Salah, B. G. Hassen, A. Mohamed Fehmi, Y. C. Hsu, J. Barea-Mendoza, C. García-Fuentes, M. Castillo-Jaramillo, H. Dominguez-Aguado, R. Viejo-Moreno, L. Terceros-Almanza, S. Bermejo Aznárez, C. Mudarra-Reche, W. Xu, M. Chico-Fernández, J. C. Montejo-González, K. Crewdson, M. Thomas, M. Merghani, L. Fenner, P. Morgan, D. Lockey, E. J. van Lieshout, B. Oomen, J. M. Binnekade, R. J. de Haan, N. P. Juffermans, M. B. Vroom, R. Algarte, L. Martínez, B. Sánchez, I. Romero, F. Martínez, S. Quintana, J. Trenado, O. Sheikh, D. Pogson, R. Clinton, F. Riccio, A. Arthur, L. Young, A. Sinclair, D. Markopoulou, K. Venetsanou, L. Filippou, E. Salla, S. Stratouli, I. Alamanos, A. H. Guirgis, R. Gutiérrez Rodriguez, M. J. Furones Lorente, I. Macias Guarasa, A. Ukere, S. Meisner, G. Greiwe, B. Opitz, D. Benten, B. Nashan, L. Fischer, C. J. C. Trepte, C. R. Behem, B. Ana, A. Vazir, D. Gibson, M. R. Hadavi, M. Riahi alam, M. R. Sasani, N. Parenti, F. Agrusta, C. Palazzi, B. Pifferi, R. Sganzerla, F. Tagliazucchi, A. Luciani, M. Möller, J. Müller-Engelmann, G. Montag, P. Adams, C. Lange, J. Neuzner, R. Gradaus, K. H. Wodack, F. Thürk, A. D. Waldmann, M. F. Grässler, S. Nishimoto, S. H. Böhm, E. Kaniusas, C. J. Trepte, M. Wallin, F. Suarez Sipman, A. Oldner, L. Colinas, R. Vicho, M. Serna, R. Cuena, A. Canabal, ECOCRITIC group, M. Etman, M. El Bahr, A. El Sakka, A. Arali, O. Bond, P. De Santis, E. Iesu, F. Franchi, S. Scolletta, F. S. Taccone, Z. Marutyan, L. Hamidova, A. Shakotko, V. Movsisyan, I. Uysupova, A. Evdokimov, S. Petrikov, F. J. Redondo Calvo, N. Bejarano, V. Baladron, R. Villazala, J. Redondo, D. Padilla, P. Villarejo, C. Gomez-Gonzalez, S. Mas-Font, A. Puppo-Moreno, M. Herrera-Gutierrez, M. Garcia-Garcia, S. Aldunate-Calvo, NEFROCON Investigators, E. P. Plata-Menchaca, X. L. Pérez-Fernández, M. Estruch, A. Betbese-Roig, P. Cárdenas Campos, M. Rojas Lora, N. D. Toapanta Gaibor, R. S. Contreras Medina, V. D. Gumucio Sanguino, E. J. Casanova, J. Sabater Riera, SIRAKI group, K. Kritmetapak, S. Peerapornratana, P. Kittiskulnam, T. Dissayabutra, P. Susantithapong, K. Praditpornsilpa, K. Tungsanga, S. Eiam-Ong, T. Winkelmann, T. Busch, J. Meixensberger, S. Bercker, E. M. Flores Cabeza, M. Sánchez Sánchez, N. Cáceres Giménez, C. Gutierrez Melón, E. Herrero de Lucas, P. Millán Estañ, M. Hernández Bernal, A. Garcia de Lorenzo y Mateos, P. A. C. Specht, M. Balik, M. Zakharchenko, F. Los, H. Brodska, C. de Tymowski, P. Augustin, M. Desmard, P. Montravers, S. N. Stapel, R. de Boer, H. M. Oudemans, A. Hollinger, T. Schweingruber, F. Jockers, M. Dickenmann, M. Siegemund, Clinical Intensive Care Research Basel, N. Runciman, L. Alban, C. Turrini, T. Sasso, T. Langer, P. Taccone, C. Marenghi, G. Grasselli, P. Wibart, T. Reginault, M. Garcia, B. Barbrel, A. Benard, C. Bader, F. Vargas, H. N. Bui, G. Hilbert, J. M. Serrano Simón, P. Carmona Sánchez, F. Ruiz Ferrón, M. García de Acilu, J. Marin, V. Antonia, L. Ruano, M. Monica, G. Hong, D. H. Kim, Y. S. Kim, J. S. Park, Y. K. Jee, Z. Yu xiang, W. Jia-xing, W. Xiao dan, N. Wen long, W. Yu, Z. Yan, X. Cheng, T. Kobayashi, Y. Onodera, R. Akimoto, A. Sugiura, H. Suzuki, M. Iwabuchi, M. Nakane, K. Kawamae, P. Carmona Sanchez, M. D. Bautista Rodriguez, M. Rodriguez Delgado, V. Martínez de Pinillos Sánchez, A. Mula Gómez, P. Beuret, C. Fortes, M. Lauer, M. Reboul, J. C. Chakarian, X. Fabre, B. Philippon-Jouve, S. Devillez, M. Clerc, N. Rittayamai, M. Sklar, M. Dres, M. Rauseo, C. Campbell, B. West, D. E. Tullis, M. Okada, N. Ahmad, M. Wood, A. Glossop, J. Higuera Lucas, A. Blandino Ortiz, D. Cabestrero Alonso, R. De Pablo Sánchez, L. Rey González, R. Costa, G. Spinazzola, A. Pizza, G. Ferrone, M. Rossi, G. Conti, H. Ribeiro, J. Alves, M. Sousa, P. Reis, C. S. Socolovsky, R. P. Cauley, J. E. Frankel, A. L. Beam, K. O. Olaniran, F. K. Gibbons, K. B. Christopher, J. Pennington, P. Zolfaghari, H. S. King, H. H. Y. Kong, H. P. Shum, W. W. Yan, C. Kaymak, N. Okumus, A. Sari, B. Erdogdu, S. Aksun, H. Basar, A. Ozcan, N. Ozcan, D. Oztuna, J. A. Malmgren, S. Lundin, K. Torén, M. Eckerström, A. Wallin, A. C. Waldenström, for the Section on Ethics of the ESICM, F. C. Riccio, A. C. P. Antonio, A. F. Leivas, F. Kenji, E. James, S. Jonnada, C. S. Gerrard, N. Jones, J. D. Salciccioli, D. C. Marshall, M. Komorowski, A. Hartley, M. C. Sykes, R. Goodson, J. Shalhoub, J. R. Fernández Villanueva, R. Fernández Garda, A. M. López Lago, E. Rodríguez Ruiz, R. Hernández Vaquero, C. Galbán Rodríguez, E. Varo Pérez, C. Hilasque, I. Oliva, G. Sirgo, M. C. Martin, M. Olona, M. C. Gilavert, M. Bodí, C. Ebm, G. Aggarwal, S. Huddart, N. Quiney, S. M. Fernandes, J. Santos Silva, J. Gouveia, D. Silva, R. Marques, H. Bento, A. Alvarez, Z. Costa Silva, D. Díaz Diaz, M. Villanova Martínez, E. Palencia Herrejon, A. Martinez de la Gandara, G. Gonzalo, M. A. Lopez, P. Ruíz de Gopegui Miguelena, C. I. Bernal Matilla, P. Sánchez Chueca, M. D. C. Rodríguez Longares, R. Ramos Abril, A. L. Ruíz Aguilar, R. Garrido López de Murillas, R. Fernández Fernández, P. Morales Laborías, M. A. Díaz Castellanos, M. E. Morales Laborías, J. Park, S. Woo, T. West, E. Powell, A. Rimmer, C. Orford, J. Williams, P. Ruiz de Gopegui Miguelena, R. S. Bourne, R. Shulman, M. Tomlin, G. H. Mills, M. Borthwick, W. Berry, D. García Huertas, F. Manzano, F. Villagrán-Ramírez, A. Ruiz-Perea, C. Rodríguez-Mejías, F. Santiago-Ruiz, M. Colmenero-Ruiz, C. König, B. Matt, A. Kortgen, C. S. Hartog, A. Wong, C. Balan, G. Barker, S. Tachaboon, J. Paratz, G. Kayambu, R. Boots, R. Vlasenko, E. Gromova, S. Loginov, M. Kiselevskiy, Y. Dolgikova, K. B. Tang, C. M. Chau, K. N. Lam, E. Gil, G. Y. Suh, C. M. Park, C. R. Chung, C. H. Lai, Y. J. Cheng, V. Colella, N. Zarrillo, M. D’Amico, F. Forfori, B. Pezza, T. Laddomada, V. Beltramelli, M. L. Pizzaballa, A. Doronzio, B. Balicco, D. Kiers, W. van der Heijden, J. Gerretsen, Q. de Mast, S. el Messaoudi, G. Rongen, M. Gomes, N. P. Riksen, Y. Kashiwagi, K. Hayashi, Y. Inagaki, S. Fujita, A. Blet, M. Sadoune, J. Lemarié, N. Bihry, R. Bern, E. Polidano, R. Merval, J. M. Launay, B. Lévy, J. L. Samuel, J. Hartmann, S. Harm, and V. Weber
Subjects: Medical emergencies. Critical care. Intensive care. First aid, RC86-88.9
Published: 2016
Full Text: View/download PDF

7. Are Public Sector Jobs Better for Ph.D. Students? The Association between Employment Sector and Doctoral Dropout and Graduation

Author: Daniel Gama e Colombo
Abstract: A growing number of doctoral students work during their Ph.D., which is commonly associated with higher risks of dropout. This paper investigates whether the sector of employment (public or private) is also a predictor of student outcomes in Ph.D. programs. Using a dataset on doctorate students in Brazil, the association of employment with the likelihood of graduation and dropout is estimated using a logistic regression and an event history analysis. The results indicate that students employed exclusively in the public sector during the program are approximately 80% more likely to graduate than those working only for private organizations.
Published: 2024
Full Text: View/download PDF

8. Immunomodulators for immunocompromised patients hospitalized for COVID-19: a meta-analysis of randomized controlled trialsResearch in context

Author: Ilias I. Siempos, Andre C. Kalil, Drifa Belhadi, Viviane Cordeiro Veiga, Alexandre Biasi Cavalcanti, Westyn Branch-Elliman, Eleni Papoutsi, Konstantinos Gkirgkiris, Nikoleta A. Xixi, Anastasia Kotanidou, Olivier Hermine, Raphaël Porcher, Xavier Mariette, Philippe Ravaud, Serge Bureau, Maxime Dougados, Matthieu Resche-Rigon, Pierre-Louis Tharaux, Annick Tibi, Elie Azoulay, Jacques Cadranel, Joseph Emmerich, Muriel Fartoukh, Bertrand Guidet, Marc Humbert, Karine Lacombe, Matthieu Mahevas, Frédéric Pene, Valerie Pourchet-Martinez, Frédéric Schlemmer, Yazdan Yazdanpanah, Gabriel Baron, Elodie Perrodeau, Damien Vanhoye, Cécile Kedzia, Lauren Demerville, Anne Gysembergh-Houal, Alexandre Bourgoin, Nabil Raked, Lakhdar Mameri, Claire Montlahuc, Lucie Biard, St.phanie Alary, Samir Hamiria, Thinhinane Bariz, Hala Semri, Dhiaa Meriem Hai, Moustafa Benafla, Mohamed Belloul, Pernelle Vauboin, Saskia Flamand, Claire Pacheco, Anouk Walter-Petrich, Emilia Stan, Souad Benarab, Corine Nyanou, Robin Charreteur, Céline Dupre, Kévin Cardet, Blandine Lehmann, Kamyl Baghli, Claire Madelaine, Eric D'Ortenzio, Oriane Puéchal, Caroline Semaille, Laurent Savale, Anatole Harrois, Samy Figueiredo, Jacques Duranteau, Nadia Anguel, Arthur Pavot, Xavier Monnet, Christian Richard, Jean-Louis Teboul, Philippe Durand, Pierre Tissieres, Mitja Jevnikar, David Montani, Stephan Pavy, Gaétane Nocturne, Samuel Bitoun, Nicolas Noel, Olivier Lambotte, Lelia Escaut, Stephane Jauréguiberry, Elodie Baudry, Christiane Verny, Edouard Lefevre, Mohamad Zaidan, Domitille Molinari, Gaël Leprun, Alain Fourreau, Laurent Cylly, Lamiae Grimaldi, Myriam Virlouvet, Ramdane Meftali, Soléne Fabre, Marion Licois, Asmaa Mamoune, Yacine Boudali, Clotilde Le Tiec, Céline Verstuyft, Anne-Marie Roques, Sophie Georgin-Lavialle, Patricia Senet, Gilles Pialoux, Angele Soria, Antoine Parrot, Helene François, Nathalie Rozensztajn, Emmanuelle Blin, Pascaline Choinier, Juliette Camuset, Jean-Simon Rech, Antony Canellas, Camille Rolland-Debord, Nadege Lemarié, Nicolas Belaube, Marine Nadal, Martin Siguier, Camille Petit-Hoang, Julie Chas, Elodie Drouet, Matthieu Lemoine, Audrey Phibel, Lucie Aunay, Eliane Bertrand, Sylviane Ravato, Marie Vayssettes, Anne Adda, Celine Wilpotte, Pélagie Thibaut, Julie Fillon, Isabelle Debrix, Soraya Fellahi, Jean-Philippe Bastard, Guillaume Lefévre, Jacques-Eric Gottenberg, Yves Hansmann, Frédéric Blanc, Sophie Ohlmann-Caillard, Vincent Castelain, Emmanuel Chatelus, Eva Chatron, Olivier Collange, François Danion, Frédéric De Blay, Pierre Diemunsch, Sophie Diemunsch, Renaud Felten, Bernard Goichot, Valentin Greigert, Aurelien Guffroy, Bob Heger, Charlotte Kaeuffer, Loic Kassegne, Anne Sophie Korganow, Pierrick Le Borgne, Nicolas Lefebvre, Paul-Michel Mertes, Eric Noll, Mathieu Oberlin, Vincent Poindron, Julien Pottecher, Yvon Ruch, François Weill, Nicolas Meyer, Emmanuel Andres, Eric Demonsant, Hakim Tayebi, Gabriel Nisand, Stéphane Brin, Cédric Sublon, Guillaume Becker, Anne Hutt, Tristan Martin, Sophie Bayer, Catherine Metzger, Arsene Mekinian, Noémie Abisror, Amir Adedjouma, Diane Bollens, Marion Bonneton, Nathalie Bourcicaux, Anne Bourrier, Maria Chauchard Thibault Chiarabiani, Doroth.e Chopin, Jonathan Cohen, Ines Devred, Bruno Donadille, Olivier Fain, Geoffrey Hariri, Vincent Jachiet, Patrick Ingliz, Marc Garnier, Marc Gatfosse, Etienne Ghrenassia, Delphine Gobert, Jessica Krause le Garrec, Cecilia Landman, Jean Remy Lavillegrand, Benedicte Lefebvre, Thibault Mahevas, Sandie Mazerand, Jean Luc Meynard, Marjolaine Morgand, Zineb Ouaz.ne, Jerome Pacanowski, S.bastien Riviere, Philippe Seksik, Harry Sokol, Heithem Soliman, Nadia Valin, Thomas Urbina, Chloé McAvoy, Maria Pereira Miranda, Gladys Aratus, Laurence Berard, Tabassome Simon, Anne Daguenel Nguyen, Elise Girault, Cl.mentine Mayala-Kanda, Marie Antignac, Céline Leplay, Jean-Benoit Arlet, Jean-Luc Diehl, Florence Bellenfant, Anne Blanchard, Alexandre Buffet, Bernard Cholley, Antoine Fayol, Edouard Flamarion, Anne Godier, Thomas Gorget, Sophie-Rym Hamada, Caroline Hauw-Berlemont, Jean-Sébastien Hulot, David Lebeaux, Marine Livrozet, Adrien Michon, Arthur Neuschwander, Marie-Aude Pennet, Benjamin Planquette, Brigitte Ranque, Olivier Sanchez, Geoffroy Volle, Sandrine Briois, Mathias Cornic, Virginie Elisee, Jesuthasan Denis, Juliette Djadi-Prat, Pauline Jouany, Ramon Junquera, Mickael Henriques, Amina Kebir, Isabelle Lehir, Jeanne Meunier, Florence Patin, Val.rie Paquet, Anne Tréhan, Véronique Vigna, Brigitte Sabatier, Damien Bergerot, Charléne Jouve, Camille Knosp, Olivia Lenoir, Nassim Mahtal, Léa Resmini, Xavier Lescure, Jade Ghosn, Antoine Bachelard, Anne Rachline, Valentina Isernia, Bao-chau, Phung, Dorothée Vallois, Aurelie Sautereau, Catherine Neukrich, Antoine Dossier, Raphaël Borie, Bruno Crestani, Gregory Ducrocq, Philippe Gabriel Steg, Philippe Dieude, Thomas Papo, Estelle Marcault, Marhaba Chaudhry, Charléne Da Silveira, Annabelle Metois, Ismahan Mahenni, Meriam Meziani, Cyndie Nilusmas, Sylvie Le Gac, Awa Ndiaye, Fran.oise Louni, Malikhone Chansombat, Zelie Julia, Solaya Chalal, Lynda Chalal, Laura Kramer, Jeniffer Le Grand, Kafif Ouifiya, Valentine Piquard, Sarah Tubiana, Yann Nguyen, Vasco Honsel, Emmanuel Weiss, Anais Codorniu, Virginie Zarrouk, Victoire de Lastours, Matthieu Uzzan, Naura Gamany, Agathe Claveirole, Alexandre Navid, Tiffanie Fouque, Yonathan Cohen, Maya Lupo, Constance Gilles, Roza Rahli, Zeina Louis, David Boutboul, Lionel Galicier, Yaël Amara, Gabrielle Archer, Amira Benattia, Anne Bergeron, Louise Bondeelle, Nathalie de Castro, Melissa Clément, Michaël Darmon, Blandine Denis, Clairelyne Dupin, Elsa Feredj, Delphine Feyeux, Adrien Joseph, Etienne Lenglin, Pierre Le Guen, Geoffroy Liégeon, Gwenaël Lorillon, Asma Mabrouki, Eric Mariotte, Grégoire Martin de Frémont, Adrien Mirouse, Jean-Michel Molina, Régis Peffault de Latour, Eric Oksenhendler, Julien Saussereau, Abdellatif Tazi, Jean-Jacques Tudesq, Lara Zafrani, Isabelle Brindele, Emmanuelle Bugnet, Karine Celli Lebras, Julien Chabert, Lamia Djaghout, Catherine Fauvaux, Anne Lise Jegu, Ewa Kozakiewicz, Martine Meunier, Marie-Thérèse Tremorin, Claire Davoine, Isabelle Madelaine, Sophie Caillat-Zucman, Constance Delaugerre, Florence Morin, Damien Sène, Ruxandra Burlacu, Benjamin Chousterman, Bruno Mégarbanne, Pascal Richette, Jean-Pierre Riveline, Aline Frazier, Eric Vicaut, Laure Berton, Tassadit Hadjam, Miguel Alejandro Vazquez-Ibarra, Clément Jourdaine, Olivia Tran, Véronique Jouis, Aude Jacob, Julie Smati, Stéphane Renaud, Claire Pernin, Lydia Suarez, Luca Semerano, Sébastien Abad, Ruben B. nainous, Nicolas Bonnet, Celine Comparon, Yves Cohen, Hugues Cordel, Robin Dhote, Nathalie Dournon, Boris Duchemann, Nathan Ebstein, Thomas Gille, Benedicte Giroux-Leprieur, Jeanne Goupil de Bouille, Hilario Nunes, Johanna Oziel, Dominique Roulot, Lucile Sese, ClaireTantet, Yurdagul Uzunhan, Coralie Bloch-Queyrat, Vincent Levy, Fadhila Messani, Mohammed Rahaoui, Myléne Petit, Sabrina Brahmi, Vanessa Rathoin, Marthe Rigal, Nathalie Costedoat-Chalumeau, Liem Binh Luong, Zakaria Ait Hamou, Sarah Benghanem, Philippe Blanche, Nicolas Carlier, Benjamin Chaigne, Remy Gauzit, Hassan Joumaa, Mathieu Jozwiak, Marie Lachétre, Hélène Lafoeste, Odie Launay, Paul Legendre, Jonathan Marey, Caroline Morbieu, Lola-Jade Palmieri, Tali-Anne Szwebel, Hendy Abdoul, Alexandra Bruneau, Audrey Beclin-Clabaux, Charly Larrieu, Pierre Montanari, Eric Dufour, Ada Clarke, Catherine Le Bourlout, Nathalie Marin, Nathalie Menage, Samira Saleh-Mghir, Mamadou Salif Cisse, Kahina Cheref, Corinne Guerin, Jérémie Zerbit, Marc Michel, Sébastien Gallien, Etienne Crickx, Benjamin Le Vavasseur, Emmanuelle Kempf, Karim Jaffal, William Vindrios, Julie Oniszczuk, Constance Guillaud, Pascal Lim, Elena Fois, Giovanna Melica, Marie Matignon, Maud Jalabert, Jean-Daniel Lelièvre, David Schmitz, Marion Bourhis, Sylia Belazouz, Laetitia Languille, Caroline Boucle, Nelly Cita, Agnés Didier, Fahem Froura, Katia Ledudal, Thiziri Sadaoui, Alaki Thiemele, Delphine Le Febvre De Bailly, Muriel Carvhalo Verlinde, Julien Mayaux, Patrice Cacoub, David Saadoun, Mathieu Vautier, Héléne Bugaut, Olivier Benveniste, Yves Allenbach, Gaëlle Leroux, Aude Rigolet, Perrine Guillaume-Jugnot, Fanny Domont, Anne Claire Desbois, Chloé Comarmond, Nicolas Champtiaux, Segolene Toquet, Amine Ghembaza, Matheus Vieira, Georgina Maalouf, Goncalo Boleto, Yasmina Ferfar, Jean-Christophe Corvol, C.line Louapre, Sara Sambin, Louise-Laure Mariani, Carine Karachi, Florence Tubach, Candice Estellat, Linda Gimeno, Karine Martin, Aicha Bah, Vixra Keo, Sabrine Ouamri, Yasmine Messaoudi, Nessima Yelles, Pierre Faye, Sebastien Cavelot, Cecile Larcheveque, Laurence Annonay, Jaouad Benhida, Aida Zahrate-Ghoul, Soumeya Hammal, Ridha Belilita, Fanny Charbonnier, Claire Aguilar, Fanny Alby-Laurent, Carole Burger, Clara Campos-Vega, Nathalie Chavarot, Benjamin Fournier, Claire Rouzaud, Damien Vimpére, Caroline Elie, Prissile Bakouboula, Laure Choupeaux, Sophie Granville, Elodie Issorat, Christine Broissand, Marie-Alexandra Alyanakian, Guillaume Geri, Nawal Derridj, Naima Sguiouar, Hakim Meddah, Mourad Djadel, Héléne Chambrin-Lauvray, Jean-Charles Duclos-vallée, Faouzi Saliba, Sophie-Caroline Sacleux, Ilias Kounis, Sonia Tamazirt, Eric Rudant, Jean-Marie Michot, Annabelle Stoclin, Emeline Colomba, Fanny Pommeret, Christophe Willekens, Rosa Da Silva, Valérie Dejean, Yasmina Mekid, Ines Ben-Mabrouk, Florence Netzer, Caroline Pradon, Laurence Drouard, Valérie Camara-Clayette, Alexandre Morel, Gilles Garcia, Abolfazl Mohebbi, Férial Berbour, Mélanie Dehais, Anne-Lise Pouliquen, Alison Klasen, Loren Soyez-Herkert, Jonathan London, Younes Keroumi, Emmanuelle Guillot, Guillaume Grailles, Younes El amine, Fanny Defrancq, Hanane Fodil, Chaouki Bouras, Dominique Dautel, Nicolas Gambier, Thierno Dieye, Boris Bienvenu, Victor Lancon, Laurence Lecomte, Kristina Beziriganyan, Belkacem Asselate, Laure Allanic, Elena Kiouris, Marie-Héléne Legros, Christine Lemagner, Pascal Martel, Vincent Provitolo, Félix Ackermann, Mathilde Le Marchand, Aurélie Chan Hew Wai, Dimitri Fremont, Elisabeth Coupez, Mireille Adda, Frédéric Duée, Lise Bernard, Antoine Gros, Estelle Henry, Claire Courtin, Anne Pattyn, Pierre-Grégoire Guinot, Marc Bardou, Agnes Maurer, Julie Jambon, Amélie Cransac, Corinne Pernot, Bruno Mourvillier, Eric Marquis, Philippe Benoit, Damien Roux, Coralie Gernez, Cécile Yelnik, Julien Poissy, Mandy Nizard, Fanette Denies, Helene Gros, Jean-Jacques Mourad, Emmanuelle Sacco, Sophie Renet, F. Ader, Y. Yazdanpanah, F. Mentre, N. Peiffer-Smadja, F.X. Lescure, J. Poissy, L. Bouadma, J.F. Timsit, B. Lina, F. Morfin-Sherpa, M. Bouscambert, A. Gaymard, G. Peytavin, L. Abel, J. Guedj, C. Andrejak, C. Burdet, C. Laouenan, D. Belhadi, A. Dupont, T. Alfaiate, B. Basli, A. Chair, S. Laribi, J. Level, M. Schneider, M.C. Tellier, A. Dechanet, D. Costagliola, B. Terrier, M. Ohana, S. Couffin-Cadiergues, H. Esperou, C. Delmas, J. Saillard, C. Fougerou, L. Moinot, L. Wittkop, C. Cagnot, S. Le Mestre, D. Lebrasseur-Longuet, V. Petrov-Sanchez, A. Diallo, N. Mercier, V. Icard, B. Leveau, S. Tubiana, B. Hamze, A. Gelley, M. Noret, E. D’Ortenzio, O. Puechal, C. Semaille, T. Welte, J.A. Paiva, M. Halanova, M.P. Kieny, E. Balssa, C. Birkle, S. Gibowski, E. Landry, A. Le Goff, L. Moachon, C. Moins, L. Wadouachi, C. Paul, A. Levier, D. Bougon, F. Djossou, L. Epelboin, J. Dellamonica, C.H. Marquette, C. Robert, S. Gibot, E. Senneville, V. Jean-Michel, Y. Zerbib, C. Chirouze, A. Boyer, C. Cazanave, D. Gruson, D. Malvy, P. Andreu, J.P. Quenot, N. Terzi, K. Faure, C. Chabartier, V. Le Moing, K. Klouche, T. Ferry, F, Valour, B. Gaborit, E. Canet, P. Le Turnier, D. Boutoille, F. Bani-Sadr, F. Benezit, M. Revest, C. Cameli, A. Caro, MJ Ngo Um Tegue, Y. Le Tulzo, B. Laviolle, F. Laine, G. Thiery, F. Meziani, Y. Hansmann, W. Oulehri, C. Tacquard, F. Vardon-Bounes, B. Riu-Poulenc, M. Murris-Espin, L. Bernard, D. Garot, O. Hinschberger, M. Martinot, C. Bruel, B. Pilmis, O. Bouchaud, P. Loubet, C. Roger, X. Monnet, S. Figueiredo, V. Godard, J.P. Mira, M. Lachatre, S. Kerneis, J. Aboab, N. Sayre, F. Crockett, D. Lebeaux, A. Buffet, J.L. Diehl, A. Fayol, J.S. Hulot, M. Livrozet, A Mekontso- Dessap, C. Ficko, F. Stefan, J. Le Pavec, J. Mayaux, H. Ait-Oufella, J.M. Molina, G. Pialoux, M. Fartoukh, J. Textoris, M. Brossard, A. Essat, E. Netzer, Y. Riault, M. Ghislain, L. Beniguel, M. Genin, L. Gouichiche, C. Betard, L. Belkhir, A. Altdorfer, V Fraipont Centro, S. Braz, JM Ferreira Ribeiro, R Roncon Alburqueque, M. Berna, M. Alexandre, B. Lamprecht, A. Egle, R. Greil, M. Joannidis, Thomas F. Patterson, Philip O. Ponce, Barbara S. Taylor, Jan E. Patterson, Jason E. Bowling, Heta Javeri, LuAnn Larson, Angela Hewlett, Aneesh K. Mehta, Nadine G. Rouphael, Youssef Saklawi, Nicholas Scanlon, Jessica J. Traenkner, Ronald P. Trible, Jr., Emmanuel B. Walter, Noel Ivey, Thomas L. Holland, Guillermo M. Ruiz-Palacios, Alfredo Ponce de León, Sandra Rajme, Lanny Hsieh, Alpesh N. Amin, Miki Watanabe, Helen S. Lee, Susan Kline, Joanne Billings, Brooke Noren, Hyun Kim, Tyler D. Bold, Victor Tapson, Jonathan Grein, Fayyaz Sutterwala, Nicole Iovine, Lars K. Beattie, Rebecca Murray Wakeman, Matthew Shaw, Mamta K. Jain, Satish Mocherla, Jessica Meisner, Amneris Luque, Daniel A. Sweeney, Constance A. Benson, Farhana Ali, Robert L. Atmar, Hana M. El Sahly, Jennifer Whitaker, Ann R. Falsey, Angela R. Branche, Cheryl Rozario, Justino Regalado Pineda, José Arturo Martinez-Orozco, David Chien Lye, Sean WX. Ong, Po Ying Chia, Barnaby E. Young, Uriel Sandkovsky, Mezgebe Berhe, Clinton Haley, Emma Dishner, Valeria D. Cantos, Colleen F. Kelley, Paulina A. Rebolledo Esteinou, Sheetal Kandiah, Sarah B. Doernberg, Pierre-Cedric B. Crouch, Hannah Jang, Anne F. Luetkemeyer, Jay Dwyer, Stuart H. Cohen, George R. Thompson, 3rd, Hien H. Nguyen, Robert W. Finberg, Jennifer P. Wang, Juan Perez-Velazquez, Mireya Wessolossky, Patrick E.H. Jackson, Taison D. Bell, Miranda J. West, Babafemi Taiwo, Karen Krueger, Johnny Perez, Triniece Pearson, Catharine I. Paules, Kathleen G. Julian, Danish Ahmad, Alexander G. Hajduczok, Henry Arguinchona, Christa Arguinchona, Nathaniel Erdmann, Paul Goepfert, Neera Ahuja, Maria G. Frank, David Wyles, Heather Young, Myoung-don Oh, Wan Beom Park, Chang Kyung Kang, Vincent Marconi, Abeer Moanna, Sushma Cribbs, Telisha Harrison, Eu Suk Kim, Jongtak Jung, Kyoung-Ho Song, Hong Bin Kim, Seow Yen Tan, Humaira Shafi, MF Jaime Chien, Raymond KC. Fong, Daniel D. Murray, Jens Lundgren, Henrik Nielsen, Tomas Jensen, Barry S. Zingman, Robert Grossberg, Paul F. Riska, Otto O. Yang, Jenny Ahn, Rubi Arias, Rekha R. Rapaka, Naomi Hauser, James D. Campbell, William R. Short, Pablo Tebas, Jillian T. Baron, Susan L.F. McLellan, Lucas S. Blanton, Justin B. Seashore, C. Buddy Creech, Todd W. Rice, Shannon Walker, Isaac P. Thomsen, Diego Lopez de Castilla, Jason W. Van Winkle, Francis X. Riedo, Surinder Kaur Pada, Alvin DY. Wang, Li Lin, Michelle Harkins, Gregory Mertz, Nestor Sosa, Louis Yi Ann Chai, Paul Anantharajah Tambyah, Sai Meng Tham, Sophia Archuleta, Gabriel Yan, David A. Lindholm, Ana Elizabeth Markelz, Katrin Mende, Richard Mularski, Elizabeth Hohmann, Mariam Torres-Soto, Nikolaus Jilg, Ryan C. Maves, Gregory C. Utz, Sarah L. George, Daniel F. Hoft, James D. Brien, Roger Paredes, Lourdes Mateu, Cora Loste, Princy Kumar, Sarah Thornton, Sharmila Mohanraj, Noreen A. Hynes, Lauren M. Sauer, Christopher J. Colombo, Christina Schofield, Rhonda E. Colombo, Susan E. Chambers, Richard M. Novak, Andrea Wendrow, Samir K. Gupta, Tida Lee, Tahaniyat Lalani, Mark Holodniy, Aarthi Chary, Nikhil Huprikar, Anuradha Ganesan, Norio Ohmagari, Ayako Mikami, D. Ashley Price, Christopher J.A. Duncan, Kerry Dierberg, Henry J. Neumann, Stephanie N. Taylor, Alisha Lacour, Najy Masri, Edwin Swiatlo, Kyle Widmer, James D. Neaton, Mary Bessesen, David S. Stephens, Timothy H. Burgess, Timothy M. Uyeki, Robert Walker, G. Lynn Marks, Anu Osinusi, Huyen Cao, Anabela Cardoso, Stephanie de Bono, Douglas E. Schlichting, Kevin K. Chung, Jennifer L. Ferreira, Michelle Green, Mat Makowski, Michael R. Wierzbicki, Tom M. Conrad, Jill Ann El-Khorazaty, Heather Hill, Tyler Bonnett, Nikki Gettinger, Theresa Engel, Teri Lewis, Jing Wang, John H. Beigel, Kay M. Tomashek, Varduhi Ghazaryan, Tatiana Beresnev, Seema Nayak, Lori E. Dodd, Walla Dempsey, Effie Nomicos, Marina Lee, Rhonda Pikaart-Tautges, Mohamed Elsafy, Robert Jurao, Hyung Koo, Michael Proschan, Tammy Yokum, Janice Arega, Ruth Florese, Jocelyn D. Voell, Richard Davey, Ruth C. Serrano, Zanthia Wiley, Varun K. Phadke, Paul A. Goepfert, Carlos A. Gomez, Theresa A. Sofarelli, Laura Certain, Hannah N. Imlay, Cameron R. Wolfe, Emily R. Ko, John J. Engemann, Nora Bautista Felix, Claire R. Wan, Sammy T. Elmor, Laurel R. Bristow, Michelle S. Harkins, Nicole M. Iovine, Marie-Carmelle Elie-Turenne, Victor F. Tapson, Pyoeng Gyun Choe, Richard A. Mularski, Kevin S. Rhie, Rezhan H. Hussein, Dilek Ince, Patricia L. Winokur, Jin Takasaki, Sho Saito, Kimberly McConnell, PharmD, David L. Wyles, Ellen Sarcone, Kevin A. Grimes, Katherine Perez, Charles Janak, Jennifer A. Whitaker, Paulina A. Rebolledo, John Gharbin, Allison A. Lambert, Diego F. Zea, Emma Bainbridge, David C. Hostler, Jordanna M. Hostler, Brian T. Shahan, Evelyn Ling, Minjoung Go, Fleesie A. Hubbard, Melony Chakrabarty, Maryrose Laguio-Vila, Edward E. Walsh, Faheem Guirgis, Vincent C. Marconi, Christian Madar, Scott A. Borgetti, Corri Levine, Joy Nock, Keith Candiotti, Julia Rozman, Fernando Dangond, Yann Hyvert, Andrea Seitzinger, Kaitlyn Cross, Stephanie Pettibone, Seema U. Nayak, and Gregory A. Deye
Subjects: Acute respiratory distress syndrome, Acute hypoxemic respiratory failure, Pneumonia, Critically ill, Cancer, Medicine (General), R5-920
Abstract: Summary: Background: Although immunomodulators have established benefit against the new coronavirus disease (COVID-19) in general, it is uncertain whether such agents improve outcomes without increasing the risk of secondary infections in the specific subgroup of previously immunocompromised patients. We assessed the effect of immunomodulators on outcomes of immunocompromised patients hospitalized for COVID-19. Methods: The protocol was prospectively registered with PROSPERO (CRD42022335397). MEDLINE, Cochrane Central Register of Controlled Trials and references of relevant articles were searched up to 01-06-2022. Authors of potentially eligible randomized controlled trials were contacted to provide data on immunocompromised patients randomized to immunomodulators vs control (i.e., placebo or standard-of-care). Findings: Eleven randomized controlled trials involving 397 immunocompromised patients hospitalized for COVID-19 were included. Ten trials had low risk of bias. There was no difference between immunocompromised patients randomized to immunomodulators vs control regarding mortality [30/182 (16.5%) vs 41/215 (19.1%); RR 0.93, 95% CI 0.61–1.41; p = 0.74], secondary infections (RR 1.00, 95% CI 0.64–1.58; p = 0.99) and change in World Health Organization ordinal scale from baseline to day 15 (weighed mean difference 0.27, 95% CI -0.09–0.63; p = 0.15). In subgroup analyses including only patients with hematologic malignancy, only trials with low risk of bias, only trials administering IL-6 inhibitors, or only trials administering immunosuppressants, there was no difference between comparators regarding mortality. Interpretation: Immunomodulators, compared to control, were not associated with harmful or beneficial outcomes, including mortality, secondary infections, and change in ordinal scale, when administered to immunocompromised patients hospitalized for COVID-19. Funding: Hellenic Foundation for Research and Innovation.
Published: 2024
Full Text: View/download PDF

9. SARS-CoV-2 infection is associated with self-reported post-acute neuropsychological symptoms within six months of follow-up

Author: Liana R. Andronescu, Stephanie A. Richard, Ann I. Scher, David A. Lindholm, Katrin Mende, Anuradha Ganesan, Nikhil Huprikar, Tahaniyat Lalani, Alfred Smith, Rupal M. Mody, Milissa U. Jones, Samantha E. Bazan, Rhonda E. Colombo, Christopher J. Colombo, Evan Ewers, Derek T. Larson, Ryan C. Maves, Catherine M. Berjohn, Carlos J. Maldonado, Caroline English, Margaret Sanchez Edwards, Julia S. Rozman, Jennifer Rusiecki, Celia Byrne, Mark P. Simons, David Tribble, Timothy H. Burgess, Simon D. Pollett, and Brian K. Agan
Subjects: Medicine, Science
Published: 2024

10. Comparison of selected exercise training modalities in the management of PCOS: A systematic review and meta-analysis to inform evidence-based guidelines

Author: Giorgia E. Colombo, Xela Dafauce Bouzo, Rhiannon K. Patten, Aya Mousa, Chau Thien Tay, Loyal Pattuwage, Helena J. Teede, Leanne M. Redman, Angelica Lindén Hirschberg, and Angelo Sabag
Subjects: Polycystic ovary syndrome, Exercise, High intensity interval training, HIIT, Moderate intensity continuous training, MICT, Sports, GV557-1198.995, Sports medicine, RC1200-1245
Abstract: Summary: Background: Polycystic ovary syndrome (PCOS) is a common endocrine condition in women of reproductive age that often presents with reproductive, metabolic, and psychological symptoms. While exercise is part of the management of PCOS, it is unclear which form of exercise may be most effective and for which outcomes. Aim: In order to inform the updated 2023 International evidence-based guideline for the assessment and management of polycystic ovary syndrome, this systematic review aimed to determine the exercise modality that provides the greatest improvement in anthropometric, metabolic, hormonal/reproductive, and psychological outcomes in adult women with PCOS. Methods: Five databases were searched from inception to July 2022. Studies eligible for inclusion consisted of those in a PCOS population, that compared two exercise modalities, and reported at least one anthropometric, metabolic, hormonal/reproductive, and/or psychological outcome. Screening, data extraction, and methodological quality assessments were conducted by two independent reviewers. Methodological quality assessment was performed using the Cochrane Risk of Bias tool and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) guidelines were used to determine the certainty of evidence. Meta-analysis was performed utilising Comprehensive Meta-Analysis software, Version 3. Results: Of the 4739 records identified, five unique studies were eligible for inclusion in the systematic review and meta-analysis, comprising a total of 216 individuals. Meta-analyses comparing high-intensity interval training (HIIT) to moderate-intensity continuous training (MICT) on anthropometric, metabolic, and hormonal/reproductive parameters found no statistically significant differences in outcomes between groups, and the certainty of evidence was graded as low or very low. Results from single studies showed that HIIT was more effective than MICT for menstrual regularity (odds ratio [95% confidence interval] = 7.875 [1.105, 56.125], p = 0.039, very low certainty). HIIT vs resistance training, and diet + MICT vs diet + MICT + resistance training were examined by a single study each, and no statistically significant differences were found for any outcome, with the certainty of evidence ranked as very low. Conclusion: To date, there are insufficient RCTs comparing exercise modalities in individuals with PCOS to establish with certainty whether one form of exercise is superior to another for the management of PCOS.
Published: 2023
Full Text: View/download PDF

11. Multiwavelength study of the gravitationally lensed blazar QSO B0218+357 between 2016 and 2020

Author: V A Acciari, S Ansoldi, L A Antonelli, A Arbet Engels, M Artero, K Asano, D Baack, A Babić, A Baquero, U Barres de Almeida, J A Barrio, I Batković, J Becerra González, W Bednarek, L Bellizzi, E Bernardini, M Bernardos, A Berti, J Besenrieder, W Bhattacharyya, C Bigongiari, A Biland, O Blanch, G Bonnoli, Ž Bošnjak, G Busetto, R Carosi, G Ceribella, M Cerruti, Y Chai, A Chilingarian, S Cikota, S M Colak, E Colombo, J L Contreras, J Cortina, S Covino, G D’Amico, V D’Elia, P Da Vela, F Dazzi, A De Angelis, B De Lotto, M Delfino, J Delgado, C Delgado Mendez, D Depaoli, F Di Pierro, L Di Venere, E Do Souto Espiñeira, D Dominis Prester, A Donini, D Dorner, M Doro, D Elsaesser, V Fallah Ramazani, A Fattorini, G Ferrara, M V Fonseca, L Font, C Fruck, S Fukami, R J García López, M Garczarczyk, S Gasparyan, M Gaug, N Giglietto, F Giordano, P Gliwny, N Godinović, J G Green, D Green, D Hadasch, A Hahn, L Heckmann, J Herrera, J Hoang, D Hrupec, M Hütten, T Inada, S Inoue, K Ishio, Y Iwamura, I Jiménez, J Jormanainen, L Jouvin, Y Kajiwara, M Karjalainen, D Kerszberg, Y Kobayashi, H Kubo, J Kushida, A Lamastra, D Lelas, F Leone, E Lindfors, S Lombardi, F Longo, R López-Coto, M López-Moya, A López-Oramas, S Loporchio, B Machado de Oliveira Fraga, C Maggio, P Majumdar, M Makariev, M Mallamaci, G Maneva, M Manganaro, K Mannheim, L Maraschi, M Mariotti, M Martínez, D Mazin, S Menchiari, S Mender, S Mićanović, D Miceli, T Miener, M Minev, J M Miranda, R Mirzoyan, E Molina, A Moralejo, D Morcuende, V Moreno, E Moretti, V Neustroev, C Nigro, K Nilsson, K Nishijima, K Noda, S Nozaki, Y Ohtani, T Oka, J Otero-Santos, S Paiano, M Palatiello, D Paneque, R Paoletti, J M Paredes, L Pavletić, P Peñil, C Perennes, M Persic, P G Prada Moroni, E Prandini, C Priyadarshi, I Puljak, W Rhode, M Ribó, J Rico, C Righi, A Rugliancich, L Saha, N Sahakyan, T Saito, S Sakurai, K Satalecka, F G Saturni, B Schleicher, K Schmidt, T Schweizer, J Sitarek, I Šnidarić, D Sobczynska, A Spolon, A Stamerra, D Strom, M Strzys, Y Suda, T Surić, M Takahashi, F Tavecchio, P Temnikov, T Terzić, M Teshima, L Tosti, S Truzzi, A Tutone, S Ubach, J van Scherpenberg, G Vanzo, M Vazquez Acosta, S Ventura, V Verguilov, C F Vigorito, V Vitale, I Vovk, M Will, C Wunderlich, D Zarić, F de Palma, F D’Ammando, A Barnacka, D K Sahu, M Hodges, T Hovatta, S Kiehlmann, W Max-Moerbeck, A C S Readhead, R Reeves, T J Pearson, A Lähteenmäki, I Björklund, M Tornikoski, J Tammi, S Suutarinen, K Hada, and K Niinuma
Published: 2021
Full Text: View/download PDF

12. Incidence of seroma in abdominoplasty with versus without the use of drains and quilting sutures: a systematic review and meta-analysis

Author: Katrienne Guidolini Martinelli, Caroline Ferraz Rezende, Felipe Gama e Colombo, and Katrini Guidolini Martinelli
Subjects: abdominoplasty, drain, suction, seroma, plastic surgery, meta-analysis, Surgery, RD1-811
Abstract: Introduction: Abdominoplasty, which aims to improve body contour, has been upgraded by its association with limited dissection of the cutaneous flap and quilting sutures in the same surgery to avoid the formation of postabdominoplasty seroma, a complication that troubles both patient and surgeon. Therefore, this study aimed to assess whether the use of quilting sutures is associated with a lower incidence of seroma after abdominoplasty than the use of drains. Methods: A systematic review of the literature and a meta-analysis were performed of the Science Direct, Scielo, Pubmed, Lilacs, CINAHL, and Scopus databases. The data analysis was performed using the Stata 12.0 program and the I2 statistic proposed by Higgins, with a 95% confidence interval for the relative risk for seroma by intervention type (drain, quilting sutures, drain with quilting sutures). The study was registered in PROSPERO (CRD42019120399). Results: Five studies met the inclusion criteria and were included in the meta-analysis. Quilting sutures showed a protective effect (versus use of drain with quilting sutures) in the prevention of seroma (relative risk, 0.13; 95% confidence interval, 0.02-0.66). Conclusion: These findings suggest that the use of quilting sutures instead of drains in abdominoplasty can effectively prevent seroma formation.
Published: 2019
Full Text: View/download PDF

13. Temporal Improvements in COVID-19 Outcomes for Hospitalized Adults: A Post Hoc Observational Study of Remdesivir Group Participants in the Adaptive COVID-19 Treatment Trial

Author: Gail E. Potter, Tyler Bonnett, Kevin Rubenstein, David A. Lindholm, Rekha R. Rapaka, Sarah B. Doernberg, David C. Lye, Richard A. Mularski, Noreen A. Hynes, Susan Kline, Catharine I. Paules, Cameron R. Wolfe, Maria G. Frank, Nadine G. Rouphael, Gregory A. Deye, Daniel A. Sweeney, Rhonda E. Colombo, Richard T. Davey, Aneesh K. Mehta, Jennifer A. Whitaker, Jose G. Castro, Alpesh N. Amin, Christopher J. Colombo, Corri B. Levine, Mamta K. Jain, Ryan C. Maves, Vincent C. Marconi, Robert Grossberg, Sameh Hozayen, Timothy H. Burgess, Robert L. Atmar, Anuradha Ganesan, Carlos A. Gomez, Constance A. Benson, Diego Lopez de Castilla, Neera Ahuja, Sarah L. George, Seema U. Nayak, Stuart H. Cohen, Tahaniyat Lalani, William R. Short, Nathaniel Erdmann, Kay M. Tomashek, and Pablo Tebas
Subjects: Adult, Prevention, Clinical Trials and Supportive Activities, Rehabilitation, Evaluation of treatments and therapeutic interventions, General Medicine, Antiviral Agents, Medical and Health Sciences, Dexamethasone, COVID-19 Drug Treatment, Phase III as Topic, Treatment Outcome, Good Health and Well Being, Clinical Trials, Phase III as Topic, Double-Blind Method, Clinical Research, 6.1 Pharmaceuticals, General & Internal Medicine, Complementary and Integrative Health, Internal Medicine, Humans, Clinical Trials, Randomized Controlled Trials as Topic
Abstract: BackgroundThe COVID-19 standard of care (SOC) evolved rapidly during 2020 and 2021, but its cumulative effect over time is unclear.ObjectiveTo evaluate whether recovery and mortality improved as SOC evolved, using data from ACTT (Adaptive COVID-19 Treatment Trial).DesignACTT is a series of phase 3, randomized, double-blind, placebo-controlled trials that evaluated COVID-19 therapeutics from February 2020 through May 2021. ACTT-1 compared remdesivir plus SOC to placebo plus SOC, and in ACTT-2 and ACTT-3, remdesivir plus SOC was the control group. This post hoc analysis compared recovery and mortality between these comparable sequential cohorts of patients who received remdesivir plus SOC, adjusting for baseline characteristics with propensity score weighting. The analysis was repeated for participants in ACTT-3 and ACTT-4 who received remdesivir plus dexamethasone plus SOC. Trends in SOC that could explain outcome improvements were analyzed. (ClinicalTrials.gov: NCT04280705 [ACTT-1], NCT04401579 [ACTT-2], NCT04492475 [ACTT-3], and NCT04640168 [ACTT-4]).Setting94 hospitals in 10 countries (86% U.S. participants).ParticipantsAdults hospitalized with COVID-19.InterventionSOC.Measurements28-day mortality and recovery.ResultsAlthough outcomes were better in ACTT-2 than in ACTT-1, adjusted hazard ratios (HRs) were close to 1 (HR for recovery, 1.04 [95% CI, 0.92 to 1.17]; HR for mortality, 0.90 [CI, 0.56 to 1.40]). Comparable patients were less likely to be intubated in ACTT-2 than in ACTT-1 (odds ratio, 0.75 [CI, 0.53 to 0.97]), and hydroxychloroquine use decreased. Outcomes improved from ACTT-2 to ACTT-3 (HR for recovery, 1.43 [CI, 1.24 to 1.64]; HR for mortality, 0.45 [CI, 0.21 to 0.97]). Potential explanatory factors (SOC trends, case surges, and variant trends) were similar between ACTT-2 and ACTT-3, except for increased dexamethasone use (11% to 77%). Outcomes were similar in ACTT-3 and ACTT-4. Antibiotic use decreased gradually across all stages.LimitationUnmeasured confounding.ConclusionChanges in patient composition explained improved outcomes from ACTT-1 to ACTT-2 but not from ACTT-2 to ACTT-3, suggesting improved SOC. These results support excluding nonconcurrent controls from analysis of platform trials in rapidly changing therapeutic areas.Primary funding sourceNational Institute of Allergy and Infectious Diseases.
Published: 2022
Full Text: View/download PDF

14. A Trajetória dos Estudantes de Pós-Graduação Stricto Sensu no Brasil: atrito e tempo para conclusão nos cursos de mestrado e doutorado

Author: Gama e Colombo, Daniel, primary
Published: 2019
Full Text: View/download PDF

15. A Desigualdade no Acesso à Pós-Graduação Stricto Sensu Brasileira: Análise do Perfil dos Ingressantes de Cursos de Mestrado e Doutorado

Author: Gama e Colombo, Daniel, primary
Published: 2019
Full Text: View/download PDF

16. Multiwavelength Variability and Correlation Studies of Mrk 421 During Historically Low X-ray and Y-ray Activity in 2015–2016

Author: Janeth Valverde Quispe, V. A. Acciari, S. Ansoldi, L. A. Antonelli, K. Asano, A. Babic, B. Banerjee, A. Baquero, U.BarresdeAlmeida, J. A. Barrio, J. Becerra Gonzalez, W. Bednarek, L. Bellizzi, E. Bernardini, M. Bernardos, A. Berti, J. Besenrieder, W. Bhattacharyya, C. Bigongiari, O. Blanch, G. Bonnoli, Z. Bosnjak, G. Busetto, R. Carosi, G. Ceribella, M. Cerruti, Y. Chai, A. Chilingarian, S. Cikota, S. M. Colak, E. Colombo, J. L. Contreras, J. Cortina, S. Covino, G. D’Amico, V. D’Elia, P. Da Vela, F. Dazzi, A. De Angelis, B. De Lotto, M. Delfino, J. Delgado, C. Delgado Mendez, D. Depaoli, T. Di Girolamo, F. Di Pierro, L. Di Venere, E. Do Souto Espineira, D. Dominis Prester, A. Donini, M. Doro, V. Fallah Ramazani, A. Fattorini, G. Ferrara, L. Foffano, M. V. Fonseca, L. Font, C. Fruck, S. Fukami, R. J. Garcıa Lopez, M. Garczarczyk, S. Gasparyan, M. Gaug, N. Giglietto, F. Giordano, P. Gliwny, N. Godinovic, J. G. Green, D. Green, D. Hadasch, A. Hahn, L. Heckmann, J. Herrera, J. Hoang, D. Hrupec, M. Hutten, T. Inada, S. Inoue, K. Ishio, Y. Iwamura, J. Jormanainen, L. Jouvin, Y. Kajiwara, M. Karjalainen, D. Kerszberg, Y. Kobayashi, H. Kubo, J. Kushida, A. Lamastra, D. Lelas, F. Leone, E. Lindfors, S. Lombardi, F. Longo, M. Lopez, R. Lopez-Coto, A. Lopez-Oramas, S. Loporchio, B. Machado de Oliveira Fraga, C. Maggio, P. Majumdar, M. Makariev, M. Mallamaci, G. Maneva, M. Manganaro, L. Maraschi, M. Mariotti, M. Martınez, D. Mazin, S. Mender, S. Micanovic, D. Miceli, T. Miener, M. Minev, J. M. Miranda, R. Mirzoyan, E. Molina, A. Moralejo, D. Morcuende, V. Moreno, E. Moretti, P. Munar-Adrover, V. Neustroev, C. Nigro, K. Nilsson, D. Ninci, K. Nishijima, K. Noda, S. Nozaki, Y. Ohtani, T. Oka, J. Otero-Santos, M. Palatiello, D. Paneque, R. Paoletti, J. M. Paredes, L. Pavletic, P. P enil, C. Perennes, M. Persic, P. G . Prada Moroni, E. Prandini, C. Priyadarshi, I. Puljak, W. Rhode, M. Ribo, J. Rico, C. Righi, A. Rugliancich, L. Saha, N. Sahakyan, T. Saito, S. Sakurai, K. Satalecka, B. Schleicher, K. Schmidt, T. Schweizer, J. Sitarek, I. Snidaric, D. Sobczynska, A. Spolon, A. Stamerra, D. Strom, M. Strzys, Y. Suda, T. Suric, M. Takahashi, F. Tavecchio, P. Temnikov, T. Terzic, M. Teshima, N. Torres-Alba, L. Tosti, S. Truzzi, J. van Scherpenberg, G. Vanzo, M. Vazquez Acosta, S. Ventura, V. Verguilov, C. F. Vigorito, V. Vitale, I. Vovk, M. Will, D. Zaric, A. Arbet-Engels, D. Baack, M. Balbo, M. Beck, N. Biederbeck, A. Biland, T. Bretz, K. Bruegge, J. Buss, D. Dorner, D. Elsaesser, D. Hildebrand, R. Iotov, M. Klinger, K. Mannheim, D. Neise, A. Neronov, M. Noethe, A. Paravac, V. Sliusar, F. Theissen, R. Walter, J. Valverde, D. Horan, M. Giroletti, M. Perri, F. Verrecchia, C. Leto, A. C. Sadun, J. W. Moody, M. Joner, A. P. Marscher, S. G. Jorstad, A. Lahteenmaki, M. Tornikoski, V. Ramakrishnan, E. Jarvela, R. J. C. Vera, S. Righini, and A.Y.Lien
Subjects: Astronomy
Abstract: We report a characterization of the multiband flux variability and correlations of the nearby (z=0.031) blazar Markarian 421(Mrk 421) using data from Mets ̈ahovi, Swift, Fermi-LAT, MAGIC, FACT, and other collaborations and instruments from 2014November till 2016 June. Mrk 421 did not show any prominent flaring activity, but exhibited periods of historically low activity above 1 TeV (F>1TeV<1.7×10−12ph cm−2s−1) and in the 2–10 keV (X-ray) band (F2−10 keV<3.6×10−11erg cm−2s−1),during which the Swift-BAT data suggest an additional spectral component beyond the regular synchrotron emission. The highest flux variability occurs in X-rays and very high-energy (E>0.1 TeV)γ-rays, which, despite the low activity, show a significant positive correlation with no time lag. The HRkeV and HRTeV show the harder-when-brighter trend observed in many blazars, but the trend flattens at the highest fluxes, which suggests a change in the processes dominating the blazar variability. Enlarging our dataset with data from years 2007 to 2014, we measured a positive correlation between the optical and the GeV emission over a range of about 60 d centred at time lag zero, and a positive correlation between the optical/GeV and the radio emission over a range of about 60 d centred at a time lag of 43+9−6d. This observation is consistent with the radio-bright zone being located about 0.2 parsec downstream from the optical/GeV emission regions of the jet. The flux distributions are better described with a lognormal function in most of the energy bands probed, indicating that the variability in Mrk 421 is likely produced by a multiplicative process.
Published: 2020
Full Text: View/download PDF

17. Low‐head dam removal increases functional diversity of stream fish assemblages

Author: Adam C. Jones, Scott J. Meiners, Eden Effert‐Fanta, Trent Thomas, Shannon C.F. Smith, and Robert E. Colombo
Subjects: Environmental Chemistry, General Environmental Science, Water Science and Technology
Published: 2022
Full Text: View/download PDF

18. Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial

Author: Cameron R Wolfe, Kay M Tomashek, Thomas F Patterson, Carlos A Gomez, Vincent C Marconi, Mamta K Jain, Otto O Yang, Catharine I Paules, Guillermo M Ruiz Palacios, Robert Grossberg, Michelle S Harkins, Richard A Mularski, Nathaniel Erdmann, Uriel Sandkovsky, Eyad Almasri, Justino Regalado Pineda, Alexandra W Dretler, Diego Lopez de Castilla, Angela R Branche, Pauline K Park, Aneesh K Mehta, William R Short, Susan L F McLellan, Susan Kline, Nicole M Iovine, Hana M El Sahly, Sarah B Doernberg, Myoung-don Oh, Nikhil Huprikar, Elizabeth Hohmann, Colleen F Kelley, Mark Holodniy, Eu Suk Kim, Daniel A Sweeney, Robert W Finberg, Kevin A Grimes, Ryan C Maves, Emily R Ko, John J Engemann, Barbara S Taylor, Philip O Ponce, LuAnn Larson, Dante Paolo Melendez, Allan M Seibert, Nadine G Rouphael, Joslyn Strebe, Jesse L Clark, Kathleen G Julian, Alfredo Ponce de Leon, Anabela Cardoso, Stephanie de Bono, Robert L Atmar, Anuradha Ganesan, Jennifer L Ferreira, Michelle Green, Mat Makowski, Tyler Bonnett, Tatiana Beresnev, Varduhi Ghazaryan, Walla Dempsey, Seema U Nayak, Lori E Dodd, John H Beigel, Andre C Kalil, Lana Wahid, Emmanuel B. Walter, Akhila G. Belur, Grace Dreyer, Jan E. Patterson, Jason E. Bowling, Danielle O. Dixon, Angela Hewlett, Robert Odrobina, Jakrapun Pupaibool, Satish Mocherla, Suzana Lazarte, Meilani Cayabyab, Rezhan H. Hussein, Reshma R. Golamari, Kaleigh L. Krill, Sandra Rajme, Paul F. Riska, Barry S. Zingman, Gregory Mertz, Nestor Sosa, Paul A. Goepfert, Mezgebe Berhe, Emma Dishner, Mohamed Fayed, Kinsley Hubel, José Arturo Martinez-Orozco, Nora Bautista Felix, Sammy T. Elmor, Amer Ryan Bechnak, Youssef Saklawi, Jason W. Van Winkle, Diego F. Zea, Maryrose Laguio-Vila, Edward E. Walsh, Ann R. Falsey, Karen Carvajal, Robert C. Hyzy, Sinan Hanna, Norman Olbrich, Jessica J. Traenkner, Colleen S. Kraft, Pablo Tebas, Jillian T Baron, Corri Levine, Joy Nock, Joanne Billings, Hyun Kim, Marie-Carmelle Elie-Turenne, Jennifer A. Whitaker, Anne F. Luetkemeyer, Jay Dwyer, Emma Bainbridge, Pyoeng Gyun Choe, Chang Kyung Kang, Nikolaus Jilg, Valeria D Cantos, Divya R. Bhamidipati, Srinivasa Nithin Gopalsamy, Aarthi Chary, Jongtak Jung, Kyoung-Ho Song, Hong Bin Kim, Constance A. Benson, Kimberly McConnell, Jennifer P. Wang, Mireya Wessolossky, Katherine Perez, Taryn A Eubank, Catherine Berjohn, Gregory C. Utz, Patrick E.H. Jackson, Taison D. Bell, Heather M. Haughey, Abeer Moanna, Sushma Cribbs, Telisha Harrison, Christopher J. Colombo, Christina Schofield, Rhonda E. Colombo, Victor F. Tapson, Jonathan Grein, Fayyaz Sutterwala, Dilek Ince, Patricia L. Winokur, Monica Fung, Hannah Jang, David Wyles, Maria G. Frank, Ellen Sarcone, Henry Neumann, Anand Viswanathan, Sarah Hochman, Mark Mulligan, Benjamin Eckhardt, Ellie Carmody, Neera Ahuja, Kari Nadeau, David Svec, Jeffrey C. Macaraeg, Lee Morrow, Dave Quimby, Mary Bessesen, Lindsay Nicholson, Jill Adams, Princy Kumar, Allison A. Lambert, Henry Arguinchona, Radica Z. Alicic, Sho Saito, Norio Ohmagari, Ayako Mikami, David Chien Lye, Tau Hong Lee, Po Ying Chia, Lanny Hsieh, Alpesh N. Amin, Miki Watanabe, Keith A. Candiotti, Jose G. Castro, Maria A. Antor, Tida Lee, Tahaniyat Lalani, Richard M. Novak, Andrea Wendrow, Scott A. Borgetti, Sarah L. George, Daniel F. Hoft, James D. Brien, Stuart H. Cohen, George R. Thompson, Melony Chakrabarty, Faheem Guirgis, Richard T. Davey, Jocelyn Voell, Jeffrey R. Strich, David A. Lindholm, Katrin Mende, Trevor R. Wellington, Rekha R. Rapaka, Jennifer S. Husson, Andrea R. Levine, Seow Yen Tan, Humaira Shafi, Jaime M F Chien, David C. Hostler, Jordanna M. Hostler, Brian T. Shahan, David H. Adams, Anu Osinusi, Huyen Cao, Timothy H. Burgess, Julia Rozman, Kevin K. Chung, Christina Nieuwoudt, Jill A. El-Khorazaty, Heather Hill, Stephanie Pettibone, Nikki Gettinger, Theresa Engel, Teri Lewis, Jing Wang, Gregory A. Deye, Effie Nomicos, Rhonda Pikaart-Tautges, Mohamed Elsafy, Robert Jurao, Hyung Koo, Michael Proschan, Tammy Yokum, Janice Arega, and Ruth Florese
Subjects: Adult, Male, Pulmonary and Respiratory Medicine, ACTT-4 Study Group, Adolescent, Clinical Trials and Supportive Activities, Clinical Sciences, Dexamethasone, Double-Blind Method, Clinical Research, Humans, Lung, Sulfonamides, Other Medical and Health Sciences, SARS-CoV-2, Prevention, Evaluation of treatments and therapeutic interventions, Middle Aged, COVID-19 Drug Treatment, Oxygen, Good Health and Well Being, Treatment Outcome, Purines, 6.1 Pharmaceuticals, Public Health and Health Services, Azetidines, Pyrazoles, Female
Abstract: BackgroundBaricitinib and dexamethasone have randomised trials supporting their use for the treatment of patients with COVID-19. We assessed the combination of baricitinib plus remdesivir versus dexamethasone plus remdesivir in preventing progression to mechanical ventilation or death in hospitalised patients with COVID-19.MethodsIn this randomised, double-blind, double placebo-controlled trial, patients were enrolled at 67 trial sites in the USA (60 sites), South Korea (two sites), Mexico (two sites), Singapore (two sites), and Japan (one site). Hospitalised adults (≥18 years) with COVID-19 who required supplemental oxygen administered by low-flow (≤15 L/min), high-flow (>15 L/min), or non-invasive mechanical ventilation modalities who met the study eligibility criteria (male or non-pregnant female adults ≥18 years old with laboratory-confirmed SARS-CoV-2 infection) were enrolled in the study. Patients were randomly assigned (1:1) to receive either baricitinib, remdesivir, and placebo, or dexamethasone, remdesivir, and placebo using a permuted block design. Randomisation was stratified by study site and baseline ordinal score at enrolment. All patients received remdesivir (≤10 days) and either baricitinib (or matching oral placebo) for a maximum of 14 days or dexamethasone (or matching intravenous placebo) for a maximum of 10 days. The primary outcome was the difference in mechanical ventilation-free survival by day 29 between the two treatment groups in the modified intention-to-treat population. Safety analyses were done in the as-treated population, comprising all participants who received one dose of the study drug. The trial is registered with ClinicalTrials.gov, NCT04640168.FindingsBetween Dec 1, 2020, and April 13, 2021, 1047 patients were assessed for eligibility. 1010 patients were enrolled and randomly assigned, 516 (51%) to baricitinib plus remdesivir plus placebo and 494 (49%) to dexamethasone plus remdesivir plus placebo. The mean age of the patients was 58·3 years (SD 14·0) and 590 (58%) of 1010 patients were male. 588 (58%) of 1010 patients were White, 188 (19%) were Black, 70 (7%) were Asian, and 18 (2%) were American Indian or Alaska Native. 347 (34%) of 1010 patients were Hispanic or Latino. Mechanical ventilation-free survival by day 29 was similar between the study groups (Kaplan-Meier estimates of 87·0% [95% CI 83·7 to 89·6] in the baricitinib plus remdesivir plus placebo group and 87·6% [84·2 to 90·3] in the dexamethasone plus remdesivir plus placebo group; risk difference 0·6 [95% CI -3·6 to 4·8]; p=0·91). The odds ratio for improved status in the dexamethasone plus remdesivir plus placebo group compared with the baricitinib plus remdesivir plus placebo group was 1·01 (95% CI 0·80 to 1·27). At least one adverse event occurred in 149 (30%) of 503 patients in the baricitinib plus remdesivir plus placebo group and 179 (37%) of 482 patients in the dexamethasone plus remdesivir plus placebo group (risk difference 7·5% [1·6 to 13·3]; p=0·014). 21 (4%) of 503 patients in the baricitinib plus remdesivir plus placebo group had at least one treatment-related adverse event versus 49 (10%) of 482 patients in the dexamethasone plus remdesivir plus placebo group (risk difference 6·0% [2·8 to 9·3]; p=0·00041). Severe or life-threatening grade 3 or 4 adverse events occurred in 143 (28%) of 503 patients in the baricitinib plus remdesivir plus placebo group and 174 (36%) of 482 patients in the dexamethasone plus remdesivir plus placebo group (risk difference 7·7% [1·8 to 13·4]; p=0·012).InterpretationIn hospitalised patients with COVID-19 requiring supplemental oxygen by low-flow, high-flow, or non-invasive ventilation, baricitinib plus remdesivir and dexamethasone plus remdesivir resulted in similar mechanical ventilation-free survival by day 29, but dexamethasone was associated with significantly more adverse events, treatment-related adverse events, and severe or life-threatening adverse events. A more individually tailored choice of immunomodulation now appears possible, where side-effect profile, ease of administration, cost, and patient comorbidities can all be considered.FundingNational Institute of Allergy and Infectious Diseases.
Published: 2022
Full Text: View/download PDF

19. An anatomical variation during para-aortic lymphadenectomy

Author: P, Leborne, M, Néron, and P E, Colombo
Subjects: Humans, Lymph Node Excision, Vena Cava, Inferior, General Medicine, Tomography, X-Ray Computed
Abstract: Failure to identify anatomical variations may contribute to surgical errors or perioperative complications during abdominal and oncological surgery. We report the case of an anatomical variation of the inferior vena cava revealed during para-aortic lymphadenectomy for advanced ovarian cancer. Due to renal insufficiency, preoperative CT-scan was performed without contrast injection and the variation was not clearly detected. Our clinical case underlines the importance of the preoperative diagnosis of anatomical variations and highlights the need to provide young surgeons with adequate technical training in para-aortic lymphadenectomy.
Published: 2022
Full Text: View/download PDF

20. Recidiva locorregional del cáncer de mama

Author: P.-E. Colombo, C. Taoum, and P. Rouanet
Published: 2022
Full Text: View/download PDF

21. This title is unavailable for guests, please login to see more information.

Author: Papakyriakopoulou, P. Balafas, E. Colombo, G. Rekkas, D.M. Kostomitsopoulos, N. Valsami, G. and Papakyriakopoulou, P. Balafas, E. Colombo, G. Rekkas, D.M. Kostomitsopoulos, N. Valsami, G.
Published: 2023

22. The Epidemiology, Immunology and Clinical Characteristics of Emerging Infectious Diseases with Pandemic Potential (EPICC) Study: Insights into COVID-19 through a Military Health System Multi-site Cohort

Author: Preventive Medicine and Biostatistics (PMB), SOM, Simon Pollett, Stephanie A. Richard, Catherine M. Berjohn, Tahaniyat Lalani, Alfred G. Smith, Rupal M. Mody, Rhonda E. Colombo, David A. Lindholm, David Saunders, Milissa U. Jones, Ryan Flanagan, Evan Ewers, David Chang, Christina Schofield, Carlos Maldonado, Katrin Mende, Andrew Wyatt, Anuradha Ganesan, Nikhil Huprikar, Samantha Bazan, Mark P. Simons, David R. Tribble, Robert O'Connell, Brian K. Agan, Timothy H. Burgess, EPICC COVID-19 Cohort Study Group, Preventive Medicine and Biostatistics (PMB), SOM, Simon Pollett, and Stephanie A. Richard, Catherine M. Berjohn, Tahaniyat Lalani, Alfred G. Smith, Rupal M. Mody, Rhonda E. Colombo, David A. Lindholm, David Saunders, Milissa U. Jones, Ryan Flanagan, Evan Ewers, David Chang, Christina Schofield, Carlos Maldonado, Katrin Mende, Andrew Wyatt, Anuradha Ganesan, Nikhil Huprikar, Samantha Bazan, Mark P. Simons, David R. Tribble, Robert O'Connell, Brian K. Agan, Timothy H. Burgess, EPICC COVID-19 Cohort Study Group
Abstract: Background The Epidemiology, Immunology and Clinical Characteristics of Emerging Infectious Diseases with Pandemic Potential (EPICC) Study: Insights into COVID-19 through a Military Health System Multi-site Cohort Simon D. Pollett1,2, Stephanie A. Richard 1,2, Catherine M. Berjohn1,3,4, Tahaniyat Lalani1,2,5, Alfred G. Smith5, Rupal M. Mody6, Rhonda E. Colombo1,2,4,7, David A. Lindholm4,8, David Saunders9, Milissa U. Jones9, Ryan Flanagan10, Evan Ewers11, David Chang11, Christina Schofield7, Carlos Maldonado12, Katrin Mende1,2,8, Andrew Wyatt13, Anuradha Ganesan1,2,14, Nikhil Huprikar14, Samantha Bazan15, Mark P. Simons1, David R. Tribble1, Robert O’Connell1, Brian K. Agan1,2, Timothy H. Burgess1 and the EPICC COVID-19 Cohort Study Group. Objective The COVID-19 pandemic posed a threat to the health of active duty and other MHS beneficiaries, as well as a threat to military readiness. The Infectious Diseases Clinical Research Program activated the Epidemiology, Immunology and Clinical Characteristics of Emerging Infectious Diseases with Pandemic Potential (EPICC) Study in early 2020 to rapidly address knowledge gaps about SARS-CoV-2 in the Military Health System (MHS). The objectives of the observational EPICC study were broad and included all aspects of COVID-19, including diagnosis, epidemiology, clinical characterization, prognosis, and evaluation of approved treatments and vaccines. Key Scientific Insights 2020-2023 (Selected) 1 Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA ; 2 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA; 3 Naval Medical Center San Diego, San Diego, CA, USA; 4 Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA 5 Naval Medical Center Portsmouth, Portsmouth, VA, USA; 6 William Beaumont Army Medical Center, El Paso, TX, USA; 7 Ma, RITM0042901, The COVID-19 pandemic posed a threat to the health of active duty and other MHS beneficiaries, as well as a threat to military readiness. The Infectious Diseases Clinical Research Program activated the Epidemiology, Immunology and Clinical Characteristics of Emerging Infectious Diseases with Pandemic Potential (EPICC) Study in early 2020 to rapidly address knowledge gaps about SARS-CoV-2 in the Military Health System (MHS).
Published: 2023

23. Characteristics and Long Term Outcomes of Cardiac Complications of SARS-CoV-2 in Youth: Results from the EPICC YES-C3 Prospective Longitudinal Cohort Module

Author: Preventive Medicine and Biostatistics (PMB), SOM, Milissa U. Jones, Stephanie A. Richard, Allison Malloy, Kirk Liesemer, Joseph May, Brian Hughes, Rhonda E. Colombo, Nikhil Huprikar, David Saunders, David A. Lindholm, Katrin Mende, Christina Schofield, Anuradha Ganesan, Erik Johnson, Charles Nguyen, Zachary Turner, Mark P. Simons, David R. Tribble, Robert O'Connell, Brian K. Agan, Timothy H. Burgess, Patrick Hickey, Craig Dobson, Simon D. Pollett, Ryan Flanagan, the EPICC COVID-19 Cohort Study Group, Preventive Medicine and Biostatistics (PMB), SOM, Milissa U. Jones, and Stephanie A. Richard, Allison Malloy, Kirk Liesemer, Joseph May, Brian Hughes, Rhonda E. Colombo, Nikhil Huprikar, David Saunders, David A. Lindholm, Katrin Mende, Christina Schofield, Anuradha Ganesan, Erik Johnson, Charles Nguyen, Zachary Turner, Mark P. Simons, David R. Tribble, Robert O'Connell, Brian K. Agan, Timothy H. Burgess, Patrick Hickey, Craig Dobson, Simon D. Pollett, Ryan Flanagan, the EPICC COVID-19 Cohort Study Group
Abstract: Table 2. Correlates of hospitalization in those infected with Omicron OR (95% CI) p a (95% CI) p Age (years) 8 (1.03, 1.14) Charlson comorbidity index 1.13 (0.88, 1.44) COVID-19 vaccination status Primary vaccine series completea 0.15 (0.02, 0.96) Boosted (additional dose)a 0.03 (0.00, 0.33) aCompared to one or zero doses, with final dose administred > 14 days before symptom onset Background Methods Disclaimer & Acknowledgements Correspondence Characteristics and Long-Term Outcomes of Cardiac Complications of SARS-CoV-2 in Youth: Results from the EPICC YES-C3 Prospective Longitudinal Cohort Module Results Results (continued) Few studies have described cardiac sequela of SARS-CoV-2 infection in young persons across the spectrum of acute COVID-19 disease severity, particularly milder outpatient cases without Multisystem Inflammatory Syndrome in Children (MIS-C). We sought to define the frequency and long term outcomes of coronary artery aneurysms, depressed cardiac function, and other cardiac complications among youth positive for SARS-CoV-2. Conclusions STUDY POPULATION The Epidemiology, Immunology, and Clinical Characteristics of Emerging Infectious Diseases with Pandemic Potential (EPICC) study is a longitudinal cohort with the primary goal of exploring the short-and long-term impact of SARS-CoV-2 infection in US Military Health System (MHS) beneficiaries enrolled at 10 military treatment facilities. CARDIAC EVALUATION Participants were scheduled for echocardiography (echo) and 12 lead electrocardiogram (ECG) at enrollment and four weeks after enrollment. Those with abnormal findings had repeated echo and ECG studies at 6 and/or 12 months; clinical data were abstracted from the medical record. Descriptive statistics were used to characterize the findings. Milissa U. Jones1, Stephanie A. Richard2,3, Allison M.W. Malloy1, Kirk Liesemer4, Rebecca Sainato4 Joseph May5, Brian Hughes1, Rhonda E. Colombo2,3,4,6, Nikhil Huprikar5, David Saunders6, David A. Lindholm6,7, Kat, RITM0043254, Few studies have described cardiac sequela of SARS-CoV-2 infection in young persons across the spectrum of acute COVID-19 disease severity, particularly milder outpatient cases without Multisystem Inflammatory Syndrome in Children (MIS-C). We sought to define the frequency and long term outcomes of coronary artery aneurysms, depressed cardiac function, and other cardiac complications among youth positive for SARS-CoV-2.
Published: 2023

24. Critical COVID-19 disease explained by type I interferon autoantibodies found in patients within the Military Health System.

Author: Preventive Medicine and Biostatistics (PMB), SOM, Maria Leondaridis, Debra Yee, Marana Tso, Elana Shaw, Lindsey B. Rosen, Emily Samuels, Paul Bastard, Jean-Laurent Casanova, Steven M. Holland, Helen C. Su, Stephanie Richard, Katrin Mende, Tahaniyat Lalani, David Lindholm, Catherine M. Berjohn, Ryan C. Maves, Rhonda E. Colombo, Christopher J. Colombo, Derek T. Larson, Evan C. Ewers, Anuradha Ganesan, Nikhil Huprikar, Rupal M. Mody, Milissa U. Jones, Mark P Simons, David Tribble, Eric D. Laing, Brian Agan, Simon Pollett, Timothy H. Burgess, Andrew L. Snow, The EPICC Study Group, Preventive Medicine and Biostatistics (PMB), SOM, Maria Leondaridis, and Debra Yee, Marana Tso, Elana Shaw, Lindsey B. Rosen, Emily Samuels, Paul Bastard, Jean-Laurent Casanova, Steven M. Holland, Helen C. Su, Stephanie Richard, Katrin Mende, Tahaniyat Lalani, David Lindholm, Catherine M. Berjohn, Ryan C. Maves, Rhonda E. Colombo, Christopher J. Colombo, Derek T. Larson, Evan C. Ewers, Anuradha Ganesan, Nikhil Huprikar, Rupal M. Mody, Milissa U. Jones, Mark P Simons, David Tribble, Eric D. Laing, Brian Agan, Simon Pollett, Timothy H. Burgess, Andrew L. Snow, The EPICC Study Group
Abstract: Background Methods Acknowledgments Correspondence Critical COVID-19 disease explained by type I interferon autoantibodies found in patients within the Military Health System. Maria Leondaridis1, Debra Yee1, Marana Tso2, Elana Shaw3, Lindsey B. Rosen3, Emily Samuels2, Paul Bastard4,5,6, Jean-Laurent Casanova4,5,6, Steven M. Holland3, Helen C. Su3, Stephanie Richard7,8, Katrin Mende7,8,9, Tahaniyat Lalani7,8,10, David Lindholm9, Catherine M. Berjohn11, Ryan C. Maves11, Rhonda E. Colombo7,8,12, Christopher J Colombo12, Derek T. Larson13, Evan C. Ewers13, Anuradha Ganesan7,8,14, Nikhil Huprikar14, Rupal M. Mody15, Milissa U. Jones16, Mark P Simons7, David Tribble7, Eric D. Laing2, Brian Agan7,8, Simon Pollett7,8, Timothy H Burgess7, Andrew L. Snow1 & the EPICC Study Group. This work was supported by awards from the Defense Health Program (HU00012020067) and the National Institute of Allergy and Infectious Disease (HU00011920111). The protocol was executed by the Infectious Disease Clinical Research Program (IDCRP), a Department of Defense (DoD) program executed by the Uniformed Services University of the Health Sciences (USUHS) through a cooperative agreement by the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF). This project has been funded in part by the National Institute of Allergy and Infectious Diseases at the National Institutes of Health, under an interagency agreement (Y1-AI-5072). The authors declare no conflicts of interest. Results Results Neutralizing auto-antibodies (auto-Abs) that target type I interferons (IFN), a group of cytokines that induce innate immune responses upon viral infection, are found within approximately 10-20% of patients with critical COVID-19. We sought to determine if neutralizing type I IFN auto- Abs contribute to severe COVID-19 in patients within the Military Health System (MHS). The Epidemiology, Immunology, and Clinical Characteristics of Emerging Infectious Diseases with Pandemic Potent, RITM0037391, Neutralizing auto-antibodies (auto-Abs) that target type I interferons (IFN), a group of cytokines that induce innate immune responses upon viral infection, are found within approximately 10-20% of patients with critical COVID-19. We sought to determine if neutralizing type I IFN auto- Abs contribute to severe COVID-19 in patients within the Military Health System (MHS). The Epidemiology, Immunology, and Clinical Characteristics of Emerging Infectious Diseases with Pandemic Potential (EPICC) cohort collected demographic data, clinical data and sera from SARS-CoV-2 infected patients enrolled across 10 U.S. military treatment facilities. We screened sera collected <21 days post-symptom onset from 249 COVID-19 inpatients and 312 COVID-19 outpatients for IFN auto-Ab positivity and neutralizing activity using Luminex and intracellular flow cytometry, respectively. Similar to previous reports, we detected neutralizing auto-Abs against IFN-? and/or IFN-? in a significantly higher frequency of inpatients (10 total, 4%) versus outpatients (1, 0.32%) (p=0.009). Remarkably, IFN auto- Abs persisted 6-12 months post-infection in most inpatients, including several with a history of autoimmune disease. Among inpatients, multivariate logistic regression analyses demonstrated that type I IFN auto-Abs were associated with a greater risk of severe and critical COVID-19 (adjusted odds ratio (aOR) = 3.99 and 4.69, respectively) after adjusting for age, sex and comorbidity burden. Our results confirm a robust association between critical COVID-19 and the presence of type I IFN auto-Abs, which may predispose to other severe respiratory viral infections that cause substantial morbidity and mortality in the MHS.
Published: 2023

25. Age-associated variations in anti-spike antibody responses in mild COVID-19 disease

Author: Pediatrics (PED), SOM, Emily Parsons, Stephanie A. Richard, Eric D. Laing, Anthony Fries, Jeffery Livezey, Milissa U. Jones, David A. Lindholm, Katrin Mende, Julia S. Rozman, Anuradha Ganesan, Tahaniyat Lalani, Alfred Smith, Rupal M. Mody, Samantha E. Bazan, David Saunders, Rhonda E. Colombo, Christopher J. Colombo, Evan C. Ewers, Derek T. Larson, Ryan Maves, Catherine M. Berjohn, Carlos J. Maldonado, Mark P. Simons, David Tribble, Brian K. Agan, Simon D. Pollett, Timothy H. Burgess, Allison M.W. Malloy, Pediatrics (PED), SOM, Emily Parsons, and Stephanie A. Richard, Eric D. Laing, Anthony Fries, Jeffery Livezey, Milissa U. Jones, David A. Lindholm, Katrin Mende, Julia S. Rozman, Anuradha Ganesan, Tahaniyat Lalani, Alfred Smith, Rupal M. Mody, Samantha E. Bazan, David Saunders, Rhonda E. Colombo, Christopher J. Colombo, Evan C. Ewers, Derek T. Larson, Ryan Maves, Catherine M. Berjohn, Carlos J. Maldonado, Mark P. Simons, David Tribble, Brian K. Agan, Simon D. Pollett, Timothy H. Burgess, Allison M.W. Malloy
Abstract: Disclaimer: The contents of this publication are the sole responsibility of the author (s) and do not necessarily reflect the views, opinions, or policies of Uniformed Services University of the Health Sciences (USU); the Department of Defense (DoD); the Departments of the Army, Navy, or Air Force; the Defense Health Agency, Brooke Army Medical Center; Walter Reed National Military Medical Center; Naval Medical Center San Diego; Madigan Army Medical Center; United States Air Force School of Aerospace Medicine; Fort Belvoir Community Hospital; William Beaumont Army Medical Center; Tripler Army Medical Center; Naval Medical Center Portsmouth; the Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.; the National Institutes of Health. Mention of trade names, commercial products, or organizations does not imply endorsement by the U.S. Government. The investigators have adhered to the policies for protection of human subjects as prescribed in 45 CFR 46. Funding: This work was supported by awards from the Defense Health Program (HU00012020067) and the National Institute of Allergy and Infectious Disease (HU00011920111). The protocol was executed by the Infectious Disease Clinical Research Program (IDCRP), a Department of Defense (DoD) program executed by the Uniformed Services University of the Health Sciences (USU) through a cooperative agreement by the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF). This project has been funded in part by the National Institute of Allergy and Infectious Diseases at the National Institutes of Health, under an interagency agreement (Y1-AI-5072). Age-associated variations in anti-spike antibody responses in mild COVID-19 disease Figure 2: Early anti-spike IgG response differed significantly by age group in contrast to late responses in those who are unvaccinated with mild disease. 2A. IgG magnitude (median fluorescence intensity, MFI) at 0-30 days post first positive (dpfp) SARS-CoV-2, RITM0036951, Background: SARS-CoV-2 most severely affects older age groups, while children experience minimal disease. We measured elements of adaptive immunity in children and adults with SARS-CoV-2 to define the age-dependent viral and host response. Methods: Participants were enrolled in the Epidemiology, Immunology, and Clinical Characteristics of Emerging Infectious Diseases with Pandemic Potential (EPICC) study. Eligibility required that individuals present with COVID-19-like symptoms between March 2020 to March 2022. Magnitude of viral RNA was determined by quantitative PCR. SARS-CoV-2-specific antibodies were measured from blood with multiplex microsphere immunoassays. Results: Serologic responses against the spike protein were measured at early and convalescent time points and compared by age, predominant infecting SARS-CoV-2 variant, and vaccination status. In those with mild (outpatient) disease, the seropositivity rates did not differ based on age. The magnitude of the anti-spike IgG response differed by age at early time points. Only the oldest age group differed at convalescent time points. Conclusions: The serologic response to SAR-CoV-2 differs with age, implicating host immunity in pathogenesis. Improved understanding of the host immune response has the potential to optimize vaccine design.
Published: 2023

26. Mechanistic Investigation of Methanol Oxidation on Au/TiO2: A Combined DRIFT and DFT Study

Author: G. D. Belletti, E. Colombo, N. Cabana, P. Quaino, and S. Collins
Subjects: General Chemistry, Catalysis
Published: 2022
Full Text: View/download PDF

27. Channel catfish and freshwater drum population demographics across four large Midwestern rivers

Author: Andrya L. Whitten, Jason A. DeBoer, Sabina Berry, Cassi Moody-Carpenter, Benjamin J. Lubinski, Neil P. Rude, John H. Chick, Robert E. Colombo, Gregory W. Whitledge, and James T. Lamer
Subjects: Aquatic Science, Ecology, Evolution, Behavior and Systematics
Published: 2022
Full Text: View/download PDF

28. Observation of inverse Compton emission from a long γ-ray burst

Author: P. Veres, P. N. Bhat, M. S. Briggs, W. H. Cleveland, R. Hamburg, C. M. Hui, B. Mailyan, R. D. Preece, O. J. Roberts, A. von Kienlin, C. A. Wilson-Hodge, D. Kocevski, M. Arimoto, D. Tak, K. Asano, M. Axelsson, G. Barbiellini, E. Bissaldi, F.Fana Dirirsa, R. Gill, J. Granot, J. McEnery, N. Omodei, S. Razzaque, F. Piron, J. L. Racusin, D. J. Thompson, S. Campana, M. G. Bernardini, N. P. M. Kuin, M. H. Siegel, S. B. Cenko, P. O’Brien, M. Capalbi, A. Daì, M. De Pasquale, J. Gropp, N. Klingler, J. P. Osborne, M. Perri, R. L. C. Starling, G. Tagliaferri, A. Tohuvavohu, A. Ursi, M.Tavani, M. Cardillo, C. Casentini, G. Piano, Y. Evangelista, F. Verrecchia, C. Pittori, F. Lucarelli, A. Bulgarelli, N. Parmiggiani, G. E. Anderson, J. P. Anderson, G. Bernardi, J. Bolmer, M. D. Caballero-García, I. M. Carrasco, A. Castellón, N. Castro Segura, A. J. Castro-Tirado, S. V. Cherukuri, A. M. Cockeram, P. D’Avanzo, A. Di Dato, R. Diretse, R. P. Fender, E. Fernández-García, J. P. U. Fynbo, A. S.Fruchter, J. Greiner, M. Gromadzki, K. E. Heintz, I. Heywood, A. J. van der Horst, Y.-D. Hu, C. Inserra, L. Izzo, V. Jaiswal, P. Jakobsson, J. Japelj, E. Kankare, D. A.Kann, C. Kouveliotou, S. Klose, A. J. Levan, X. Y. Li, S. Lotti, K. Maguire, D. B. Malesani, I. Manulis, M. Marongiu, S. Martin, A. Melandri, M. J.Michałowski, J. C. A. Miller-Jones, K. Misra, A. Moin, K. P. Mooley, S. Nasri, M. Nicholl, A. Noschese, G. Novara, S. B. Pandey, E. Peretti, C. J. Pérez del Pulgar, M. A. Pérez-Torres, D. A. Perley, L. Piro, F. Ragosta, L. Resmi, R. Ricci, A. Rossi, R. Sánchez-Ramírez, J. Selsing, S. Schulze, S. J. Smartt, I. A. Smith, V. V. Sokolov, J. Stevens, N. R. Tanvir, C. C. Thöne, A. Tiengo, E. Tremou, E. Troja, A. de Ugarte Postigo, A. F. Valeev, S. D. Vergani, M. Wieringa, P. A. Woudt, D. Xu, O. Yaron, D. R. Young, V. A. Acciari, S. Ansoldi, L. A. Antonelli, A. Arbet Engels, D. Baack, A. Babić, B. Banerjee, U. Barres de Almeida, J. A. Barrio, J. Becerra González, W. Bednarek, L. Bellizzi, E. Bernardini, A. Berti, J. Besenrieder, W. Bhattacharyya, C. Bigongiari, A. Biland, O. Blanch, G. Bonnoli, Ž. Bošnjak, G. Busetto, R. Carosi, G. Ceribella, Y. Chai, A. Chilingaryan, S. Cikota, S. M. Colak, U. Colin, E. Colombo, J. L. Contreras, J. Cortina, S. Covino, V. D’Elia, P. Da Vela, F. Dazzi, A. De Angelis, B. De Lotto, M. Delfino, J. Delgado, D. Depaoli, F. Di Pierro, L. Di Venere, E. Do Souto Espiñeira, D. Dominis Prester, A. Donini, D. Dorner, M. Doro, D. Elsaesser, V. Fallah Ramazani, A. Fattorini, G. Ferrara, D. Fidalgo, L. Foffano, M. V. Fonseca, L. Font, C. Fruck, S. Fukami, R. J. García López, M. Garczarczyk, S.Gasparyan, M. Gaug, N. Giglietto, F. Giordano, N. Godinović, D. Green, D. Guberman, D. Hadasch, A. Hahn, J. Herrera, J. Hoang, D. Hrupec, M. Hütten, T. Inada, S. Inoue, K. Ishio, Y. Iwamura, L. Jouvin, D. Kerszberg, H. Kubo, J. Kushida, A. Lamastra, D. Lelas, F. Leone, E. Lindfors, S. Lombardi, F. Longo, M. López, R. López-Coto, A. López-Oramas, S. Loporchio, B. Machado de Oliveira Fraga, C. Maggio, P. Majumdar, M. Makariev, M. Mallamaci, G. Maneva, M. Manganaro, K. Mannheim, L. Maraschi, M. Mariotti, M. Martínez, D. Mazin, S. Mićanović, D. Miceli, M. Minev, J. M. Miranda, R. Mirzoyan, E. Molina, A. Moralejo, D. Morcuende, V. Moreno, E. Moretti, P. Munar-Adrover, V. Neustroev, C. Nigro, K. Nilsson, D. Ninci, K. Nishijima, K. Noda, L. Nogués, S. Nozaki, S. Paiano, M. Palatiello, D. Paneque, R. Paoletti, J. M. Paredes, P. Peñil, M. Peresano, M. Persic, P. G. Prada Moroni, E. Prandini, I. Puljak, W. Rhode, M. Ribó, J. Rico, C. Righi, A. Rugliancich, L. Saha, N. Sahakyan, T. Saito, S. Sakurai, K. Satalecka, K. Schmidt, T. Schweizer, J. Sitarek, I. Šnidarić, D. Sobczynska, A. Somero, A. Stamerra, D. Strom, M. Strzys, Y. Suda, T. Surić, M. Takahashi, F. Tavecchio, P. Temnikov, T. Terzić, M. Teshima, N. Torres-Albà, L. Tosti, V. Vagelli, J. van Scherpenberg, G. Vanzo, M. Vazquez Acosta, C. F. Vigorito, V. Vitale, I. Vovk, M. Will, D. Zarić, and L. Nava
Subjects: Space Sciences (General)
Abstract: Long-duration γ-ray bursts (GRBs) originate from ultra-relativistic jets launched from the collapsing cores of dying massive stars. They are characterized by an initial phase of bright and highly variable radiation in the kiloelectronvolt-to-megaelectronvolt band, which is probably produced within the jet and lasts from milliseconds to minutes, known as the prompt emission. Subsequently, the interaction of the jet with the surrounding medium generates shock waves that are responsible for the afterglow emission, which lasts from days to months and occurs over a broad energy range from the radio to the gigaelectronvolt bands. The afterglow emission is generally well explained as synchrotron radiation emitted by electrons accelerated by the external shock. Recently, intense long-lasting emission between 0.2 and 1 teraelectronvolts was observed from GRB 190114C. Here we report multifrequency observations of GRB 190114C, and study the evolution in time of the GRB emission across 17 orders of magnitude in energy, from 5 × 10^(−6) to 10^(12) electronvolts. We find that the broadband spectral energy distribution is double-peaked, with the teraelectronvolt emission constituting a distinct spectral component with power comparable to the synchrotron component. This component is associated with the afterglow and is satisfactorily explained by inverse Compton up-scattering of synchrotron photons by high-energy electrons. We find that the conditions required to account for the observed teraelectronvolt component are typical for GRBs, supporting the possibility that inverse Compton emission is commonly produced in GRBs.
Published: 2019
Full Text: View/download PDF

29. Access to graduate education in Brazil: Predictors of choice and enrollment in master’s degree programs

Author: Daniel Gama e Colombo
Subjects: Medical education, Graduate education, inequity of access, Microdata (statistics), conditional logit, Logistic regression, Low mobility, Master s degree, Odds, Disadvantaged, Economics as a science, Brazilian education, ComputingMilieux_COMPUTERSANDEDUCATION, Psychology, Socioeconomic status, graduate education, HB71-74
Abstract: This paper presents an assessment of the factors associated with access to master’s degree programs in Brazil, investigating whether there is evidence of inequity arising from students’ personal and socioeconomic characteristics. A rich and novel dataset comprising microdata on undergraduate college graduates and new master’s students is used for the empirical analysis. Students’ decisions to progress to graduate education are modeled as a two-stage process, and the parameters are estimated separately for each broad academic field using a conditional logit model for the first stage, and a logistic regression analysis for the second stage. The main findings are: (a) there is strong evidence of low mobility of students starting graduate education, and they are far more likely to choose a master’s degree program in the same university or close to where they graduated from college; (b) academic performance and activities during undergraduate program in college are associated with an increase in the relative odds of progressing to graduate education; (c) in most broad academic fields, no evidence that women, black or brown students, economically disadvantaged students, foreigners and people with disabilities are less likely to start a master’s program is found; and (d) a significant association between the odds of enrollment and parental education is not observed in nearly all fields. The study points to different recommendations and to further research questions to understand and improve graduate education in Brazil.
Published: 2022

30. 1066. Precision phenotyping of 'long COVID' through machine learning

Author: Nusrat J Epsi, David A Lindholm, Anuradha Ganesan, Tahaniyat Lalani, Alfred G Smith, Rupal Mody, Milissa Jones, Samantha Bazan, Rhonda E Colombo, Christopher Colombo, Evan C Ewers, Derek Larson, Catherine M Berjohn, Ryan C Maves, Anthony C Fries, Ann Scher, Celia Byrne, Jennifer Rusiecki, Margaret Sanchez Edwards, Julia S Rozman, Katrin Mende, Mark P Simons, David R Tribble, Brian Agan, Timothy Burgess, Simon Pollett, and Stephanie A Richard
Subjects: Infectious Diseases, Oncology
Abstract: Background Characterizing, diagnosing, and caring for “long COVID” patients has proven to be challenging due to heterogenous symptoms and broad definitions of these post-acute sequelae. Here, we take a machine learning approach to identify discrete clusters of long COVID symptoms which may define specific long COVID phenotypes. Figure 1: (A) Principal component analysis followed by K-means clustering identified three groups of participants. (B) Heatmap depicting three distinct clusters (high values are in red and low value are in blue); Cluster 1 exhibits sensory symptoms (e.g., loss of smell and/or taste), Cluster 2 exhibits fatigue and difficulty thinking (e.g., changes in ability to think) symptoms, and Cluster 3 exhibits difficulty breathing and exercise intolerance symptoms. (C) Clinical and demographic characteristics of 97 military health system beneficiaries by identified clusters Methods The Epidemiology, Immunology, and Clinical Characteristics of Emerging Infectious Diseases with Pandemic Potential (EPICC) study is a longitudinal COVID-19 cohort study with data and biospecimens collected from 10 military treatment facilities and online recruitment. Demographic and clinical characteristics were collected using case report forms and surveys completed at enrollment and at 1, 3, 6, 9, and 12 months. For this analysis, we identified those who reported any moderate to severe persistent symptoms on surveys collected 6-months post-COVID-19 symptom onset. Using the survey responses, we applied principal component analysis (PCA) followed by unsupervised machine learning clustering algorithm K-means to identify groups with distinct clusters of symptoms. Results Of 1299 subjects with 6-month survey responses, 97 (7.47%) reported moderate to severe persistent symptoms. Among these subjects, three clusters were identified using PCA (Figure 1A). Cluster 1 is characterized by sensory symptoms (loss of taste and/or smell), Cluster 2 by fatigue and difficulty thinking, and Cluster 3 by difficulty breathing and exercise intolerance (Figure 1B). More than half of these subjects (57%) were female, 64% were 18-44 years old, and 64% had no comorbidities at enrollment (Figure 1C). Those in the sensory symptom cluster were all outpatients at the time of initial COVID-19 presentation (p < 0.01). The difficulty breathing and exercise intolerance symptom-clusters had a higher proportion of older participants (Age group ≥ 45-64) with more comorbidities (CCI ≥ 1-2). Conclusion We identified three distinct ‘long COVID’ phenotypes among those with moderate to severe COVID-19 symptoms at 6-months post-symptom onset. With further validation and characterization, this framework may allow more precise classification of long COVID cases, and potentially improve the diagnosis, prognosis, and treatment of post- infectious sequelae. Disclosures Ryan C. Maves, MD, AiCuris: Grant/Research Support|Sound Pharmaceuticals: Grant/Research Support|Trauma Insights, LLC: Advisor/Consultant Julia S. Rozman, n/a, Astra Zeneca: The HJF, in support of the USU IDCRP, was funded to conduct or augment unrelated Phase III Mab and vaccine trials as part of US Govt. COVID19 response Mark P. Simons, PhD, AstraZeneca: The HJF, in support of the USU IDCRP, was funded to conduct or augment unrelated Phase III Mab and vaccine trials as part of US Govt. COVID19 response David R. Tribble, DrPH, AstraZeneca: The HJF, in support of the USU IDCRP, was funded to conduct or augment unrelated Phase III Mab and vaccine trials as part of US Govt. COVID19 response Timothy Burgess, MD, MPH, AstraZeneca: The HJF, in support of the USU IDCRP, was funded to conduct or augment unrelated Phase III Mab and vaccine trials as part of US Govt. COVID19 response Simon Pollett, MBBS, Astra Zeneca: The HJF, in support of the USU IDCRP, was funded to conduct or augment unrelated Phase III Mab and vaccine trials as part of US Govt. COVID19 response.
Published: 2022
Full Text: View/download PDF

31. 1056. Correlates of Omicron SARS-CoV-2 viral load: diagnostic and clinical implications

Author: Simon Pollett, Stephanie A Richard, Anthony C Fries, Allison M Malloy, Anuradha Ganesan, Jeffrey Livezey, David Saunders, Nikhil Huprikar, Rupal Mody, Katrin Mende, David A Lindholm, Catherine M Berjohn, Julia S Rozman, Milissa Jones, Christopher Colombo, Rhonda E Colombo, David Tribble, Mark P Simons, Brian Agan, and Timothy Burgess
Subjects: Infectious Diseases, Oncology
Abstract: Background Omicron SARS-CoV-2 infections are associated with less frequent olfactory sensory loss and a predominance of pharyngitis symptoms compared to prior variants, with proposed diagnostic implications. We examined whether such symptomology predicts a higher RNA abundance in the oropharynx. We further investigated how age, symptom-day, vaccination history and clinical severity correlate with viral load to inform clinical prognostication and transmission modeling. Methods The EPICC study is a longitudinal cohort of COVID-19 cases enrolled through U.S military medical treatment facilities. Demographic and clinical characteristics were measured with interviews and surveys. Nasopharyngeal (NP), oropharyngeal (OP) and nasal swabs (NS) were collected for SARS-CoV-2 qPCR and sequence genotyping. Multivariable linear regression models were fit to estimate the effect of anatomical site on SARS-CoV-2 RNA abundance (a proxy for viral load), adjusting for sampling time, vaccine history and host age. Results We analyzed 77 sequence-confirmed Omicron cases; no BA.2 cases were detected. The median age was 38.8 years. 81.8% were vaccinated and 15.6% cases were hospitalized. 80.0%, 21.8%, and 65.5% reported nasal congestion, loss of smell or taste, and sore throat, respectively. The median RNA abundance was lowest in OP swabs (p < 0.001) (Fig 1). Linear regression confirmed that OP sampling was associated with lower viral load (p < 0.001). We further noted that greater age and symptom-day were independent correlates of viral load (Table 1). By bivariate analysis there was a trend toward lower RNA abundance in vaccinated subjects (p = 0.35). RNA abundance (at any site) was substantially higher in hospitalized (10634 N2 genome equivalents [GE]/reaction) versus outpatient cases (1419 N1 GE/reaction) but this was not statistically significant (p = 0.26). Fig 1.RNA abundance by upper respiratory swab anatomical location of collection (n = 142 swabs from n = 77 subjects) Conclusion We noted prevalent sore throat symptoms and infrequent sensory loss in Omicron cases. Despite this, viral load was highest in NP/NS collected swabs as has been noted in prior variants. We note an age correlation with RNA abundance, and provide a viral load decay rate which may be useful for transmission modeling. Vaccination and clinical severity may also correlate with Omicron viral load, as noted with prior SARS-CoV-2 variants. Disclosures Simon Pollett, MBBS, Astra Zeneca: The HJF, in support of the USU IDCRP, was funded to conduct or augment unrelated Phase III Mab and vaccine trials as part of US Govt. COVID19 response Julia S. Rozman, n/a, Astra Zeneca: The HJF, in support of the USU IDCRP, was funded to conduct or augment unrelated Phase III Mab and vaccine trials as part of US Govt. COVID19 response David Tribble, MD, DrPH, Astra Zeneca: The HJF, in support of the USU IDCRP, was funded to conduct or augment unrelated Phase III Mab and vaccine trials as part of US Govt. COVID19 response Mark P. Simons, PhD, AstraZeneca: The HJF, in support of the USU IDCRP, was funded to conduct or augment unrelated Phase III Mab and vaccine trials as part of US Govt. COVID19 response Timothy Burgess, MD, MPH, AstraZeneca: The HJF, in support of the USU IDCRP, was funded to conduct or augment unrelated Phase III Mab and vaccine trials as part of US Govt. COVID19 response.
Published: 2022
Full Text: View/download PDF

32. 80. SARS-CoV-2 infection is associated with decreased reported physical fitness in a US military longitudinal cohort

Author: Stephanie A Richard, Ann Scher, Jennifer Rusiecki, Celia Byrne, Catherine M Berjohn, Anthony C Fries, Tahaniyat Lalani, Alfred G Smith, Rupal Mody, Anuradha Ganesan, Nikhil Huprikar, Rhonda E Colombo, Christopher Colombo, David A Lindholm, Katrin Mende, Milissa Jones, Derek Larson, Evan C Ewers, Samantha Bazan, Charlotte Lanteri, David Saunders, Ryan C Maves, Jeffrey Livezey, Margaret Sanchez Edwards, Julia S Rozman, David R Tribble, Brian Agan, Simon Pollett, Mark P Simons, and Timothy Burgess
Subjects: Infectious Diseases, Oncology
Abstract: Background COVID-19 may have deleterious effects on the fitness of active duty US military service members. We seek to understand the long-term functional consequences of SARS-CoV-2 infection in this critical population, and in other military healthcare beneficiaries. Methods The Epidemiology, Immunology, and Clinical Characteristics of Emerging Infectious Diseases with Pandemic Potential (EPICC) study is a longitudinal cohort study to describe the outcomes of SARS-CoV-2 infection in US Military Health System beneficiaries. Subjects provided information about difficulties experienced with daily activities, exercise, and physical fitness performance via electronic surveys. Subjects completed surveys at enrollment and at 1, 3, 6, 9, and 12 months. Results 5,910 subjects completed survey fitness questions, 3,244 (55%) of whom tested SARS-CoV-2 positive at least once during the period of observation. Over 75% of subjects were young adults and over half were male (Table 1). 1,093 (34.3%) of SARS-CoV-2-positive subjects reported new or increased difficulty exercising compared to 393 (14.8%) SARS-CoV-2 negative subjects (p < 0.01) (Table 2). The most commonly reported symptoms related to problems with exercise and activities were dyspnea and fatigue. Among the active-duty members who answered the question about their service-mandated physical fitness test scores, 43.2% of SARS-CoV-2-positive participants reported that their scores had worsened in the study period, compared with 24.3% of SARS-CoV-2 negative participants. Among SARS-CoV-2-positive subjects, reports of difficulty exercising and performing daily activities were highest within one month of the first positive test, decreasing in prevalence among the cohort only slightly to 24% and 18%, respectively, at 12 months (Figure 1). Conclusion A substantial proportion of military service-members in this cohort have reported impairment of their service-mandated physical fitness scores after COVID-19; this proportion is significantly higher than those who are SARS-CoV-2 negative and persists to 12 months in many; similar complaints were reported among non-active duty. Further objective evaluation of post-COVID fitness impairment in this population is warranted. Disclosures Ryan C. Maves, MD, AiCuris: Grant/Research Support|Sound Pharmaceuticals: Grant/Research Support|Trauma Insights, LLC: Advisor/Consultant Julia S. Rozman, n/a, Astra Zeneca: The HJF, in support of the USU IDCRP, was funded to conduct or augment unrelated Phase III Mab and vaccine trials as part of US Govt. COVID19 response David R. Tribble, DrPH, AstraZeneca: The HJF, in support of the USU IDCRP, was funded to conduct or augment unrelated Phase III Mab and vaccine trials as part of US Govt. COVID19 response Simon Pollett, MBBS, Astra Zeneca: The HJF, in support of the USU IDCRP, was funded to conduct or augment unrelated Phase III Mab and vaccine trials as part of US Govt. COVID19 response Mark P. Simons, PhD, AstraZeneca: The HJF, in support of the USU IDCRP, was funded to conduct or augment unrelated Phase III Mab and vaccine trials as part of US Govt. COVID19 response Timothy Burgess, MD, MPH, AstraZeneca: The HJF, in support of the USU IDCRP, was funded to conduct or augment unrelated Phase III Mab and vaccine trials as part of US Govt. COVID19 response.
Published: 2022
Full Text: View/download PDF

33. 1102. The Host Response to SARS-CoV-2 Infection Differs by Age

Author: Emily Parsons, Stephanie A Richard, Eric D Laing, Anthony C Fries, Jeffrey Livezey, Milissa Jones, David A Lindholm, Katrin Mende, Julia S Rozman, Anuradha Ganesan, Nikhil Huprikar, Tahaniyat Lalani, Alfred G Smith, Rupal Mody, Samantha Bazan, David Saunders, Rhonda E Colombo, Christopher Colombo, Evan C Ewers, Derek Larson, Ryan C Maves, Catherine M Berjohn, Carlos Maldonado, Mark P Simons, David Tribble, Brian Agan, Timothy Burgess, Simon Pollett, and Allison M Malloy
Subjects: Infectious Diseases, Oncology
Abstract: Background Infection with SARS-CoV-2 and the resulting host immune response has been primarily characterized in middle and older aged populations due to a higher incidence of symptoms in these age groups. Due to reduced severity of disease, children were poorly studied and assumed to be less frequently infected compared to older age groups. We measured the viral load and adaptive immune response across the age-spectrum to define the age-dependent viral and host responses. Methods From March 2020-March 2022, we enrolled individuals across the age spectrum who presented to U.S. military medical treatment facilities with COVID-19-like symptoms. In this longitudinal cohort study, demographic and clinical data were collected in addition to nasopharyngeal swabs and peripheral blood. Magnitude of viral RNA was measured by quantitative PCR (qPCR) from nasopharyngeal samples and SARS-CoV-2-specific IgG antibodies were measured from blood with multiplex microsphere immunoassays. Results 4,768 SARS-CoV-2 positive participants were enrolled, among whom 42, 64, 89, 380, 948 and 245 individuals were in age brackets 0-4y, 5-11y, 12-17y, 18-44, 45-64y, and >65y, respectively. Viral load as measured by qPCR was determined to be similar across age groups within the first week post symptom onset. The magnitude of the IgG antibody response against the spike protein was also compared across age groups at early and convalescent time points and was higher in those over the age of 65 years. Conclusion Early viral load during acute infection did not correlate with age in individuals who experienced COVID-19. These findings diverge from other respiratory viruses, such as respiratory syncytial virus and influenza where children tend to have higher viral loads. In contrast, the magnitude of the antibody response against the spike protein correlated with older age at acute and convalescent time points. Together our data suggest that the host response against SAR-CoV-2 differs with age and is not associated with the acute viral load. Defining age-dependent immunity against SARS-CoV-2 has the potential to identify key immunologic responses that can be used to optimize treatment and vaccine strategies. Disclosures Julia S. Rozman, n/a, Astra Zeneca: The HJF, in support of the USU IDCRP, was funded to conduct or augment unrelated Phase III Mab and vaccine trials as part of US Govt. COVID19 response Ryan C. Maves, MD, AiCuris: Grant/Research Support|Sound Pharmaceuticals: Grant/Research Support|Trauma Insights, LLC: Advisor/Consultant Mark P. Simons, PhD, AstraZeneca: The HJF, in support of the USU IDCRP, was funded to conduct or augment unrelated Phase III Mab and vaccine trials as part of US Govt. COVID19 response David Tribble, MD, DrPH, Astra Zeneca: The HJF, in support of the USU IDCRP, was funded to conduct or augment unrelated Phase III Mab and vaccine trials as part of US Govt. COVID19 response Timothy Burgess, MD, MPH, AstraZeneca: The HJF, in support of the USU IDCRP, was funded to conduct or augment unrelated Phase III Mab and vaccine trials as part of US Govt. COVID19 response Simon Pollett, MBBS, Astra Zeneca: The HJF, in support of the USU IDCRP, was funded to conduct or augment unrelated Phase III Mab and vaccine trials as part of US Govt. COVID19 response.
Published: 2022
Full Text: View/download PDF

34. 273. Emergence of the SARS-CoV-2 Omicron Variant in the Pragmatic Assessment of Influenza Vaccine Effectiveness in the Department of Defense (PAIVED) Study

Author: Stephanie A Richard, Catherine M Berjohn, Limone Collins, Srihari Seshadri, Christina Spooner, Wesley R Campbell, Anuradha Ganesan, Anthony C Fries, David Hrncir, Tahaniyat Lalani, Tyler Warkentien, Ana E Markelz, Katrin Mende, Bruce McClenathan, John H Powers, Jitendrakumar Modi, Christina Schofield, Alan Williams, Rhonda E Colombo, and Timothy Burgess
Subjects: Infectious Diseases, Oncology
Abstract: Background Novel SARS-CoV-2 (SCV2) variants may differ in epidemiology and clinical impact. PAIVED, a randomized trial comparing the efficacy of 3 different platforms of inactivated influenza vaccines in adult military health system beneficiaries, actively surveils participants for influenza-like illness (ILI), including COVID-19, and conducts targeted investigations among those who develop ILI. The current season (2021/22) offered an opportunity to assess symptomatology associated with emerging SCV2 variants in this prospective cohort. Methods Following receipt of influenza vaccine, PAIVED participants receive a weekly email or text message querying for ILI symptoms. Those who reported ILI completed a validated symptom diary (FLU-PRO Plus) daily for 7 days and collected a nasal swab. Nasal specimens underwent multiplex PCR testing, followed by SCV2 genome sequencing as applicable. PAIVED study participants from the 2021-22 influenza season who reported an ILI, had confirmed infection with SCV2 for which sequence data is available, and completed at least one FLU-PRO Plus survey were included in this analysis. Results To date, 293 participants (7% of active cohort; 22.5% reporting ILI) tested positive for SCV2; sequencing has identified 23 Delta and 200 Omicron variants (199 BA.1, 1 BA.2). Among the 212 participants with sequenced SCV2 and symptom data, 55% were male, 57% were white, and 85% were active-duty military (Table 1). Overall, peak symptom severity was classified as mild to moderate in 79.3% of cases, fever duration averaged 2.5±2.2 days, and there were activity limitations for a mean of 5.2±3.8 days. No differences in maximum symptom scores (total or by domain) were detected for participants infected with Omicron compared to Delta. Figure 1 depicts variation in mean symptom scores by day of ILI, grouped by variant. Table 1.Demographic characteristics of PAIVED study participants with Delta and Omicron SARS-CoV-2 variants during the 2021/22 season.Figure 1.Mean FLU-PRO Plus domain and total scores by days since identification of an influenza-like illness in participants with Omicron or Delta variants of SARS-CoV-2 in the 2021/22 season of PAIVED. Conclusion Omicron emerged as the predominant SCV2 variant causing ILI in our cohort this season, typically manifesting with mild symptoms. Further exploration of potential differences in ILI experience between SCV2 variants and other ILI causes, plus the impact and timing of vaccination, will add insight into the relative contribution of such factors on symptomatology. Disclosures John H. Powers, III, MD, Arrevus: Advisor/Consultant|Eicos: Advisor/Consultant|Evofem: Advisor/Consultant|Eyecheck: Advisor/Consultant|Gilead: Advisor/Consultant|GlaxoSmithKline: Advisor/Consultant|OPKO: Advisor/Consultant|Resolve: Advisor/Consultant|Romark: Advisor/Consultant|SpineBioPharma: Advisor/Consultant|UTIlity: Advisor/Consultant|Vir: Advisor/Consultant Jitendrakumar Modi, MD, GlaxoSmithKline: I am a paid speaker for GSK. I do not speak for their flu brand. Timothy Burgess, MD, MPH, AstraZeneca: The HJF, in support of the USU IDCRP, was funded to conduct or augment unrelated Phase III Mab and vaccine trials as part of US Govt. COVID19 response.
Published: 2022
Full Text: View/download PDF

35. 2206. Pragmatic Assessment of Influenza Vaccine Effectiveness in the Department of Defense (PAIVED): Updates from Year 4 of a Multi-site Trial

Author: Timothy Burgess, Stephanie A Richard, Limone Collins, Christina Spooner, Srihari Seshadri, Christina Schofield, Anuradha Ganesan, Wesley R Campbell, David Hrncir, Tahaniyat Lalani, Tyler Warkentien, Katrin Mende, Ana E Markelz, Catherine M Berjohn, Bruce McClenathan, Jitendrakumar Modi, Alan Williams, and Rhonda E Colombo
Subjects: Infectious Diseases, Oncology
Abstract: Background The effectiveness of the influenza vaccine is varies with circulating strain concordance and timing of influenza spread in a community. The Pragmatic Assessment of Influenza Vaccine Effectiveness in the DoD (PAIVED) study is a multi-year, randomized clinical trial of three FDA-licensed vaccine types (egg-based, cell-based, and recombinant), designed to determine which influenza vaccine platform is most effective among adults in a military setting. Figure 1.PAIVED summary flow chart Methods Participants in the fourth year of PAIVED (2021-22 influenza season) were enrolled from September 2021 through January 2022 at 9 military facilities. Participants were asked each week about influenza-like illness (ILI) symptoms. If the participants reported ILI symptoms, research staff scheduled an acute and convalescent ILI visit. Additional details about the study are included in Figure 1. Results In year 4, 4,688 participants were enrolled, among whom 63.8% were male, 56.5% were white, and the average age was 34 years (Tables 1 and 2). As of early April, 1,297 ILIs had been reported. Most participants reported a single ILI (987 (87%)), while 140 participants reported two ILIs and 10 reported three ILIs. The mean duration of the reported ILIs was 11 days, with a mean 5 days of limited activity. Three participants were hospitalized. Among the samples processed to date, influenza has been identified in four participants. The most common pathogens in year 4 were SARS-CoV-2 and rhino/enterovirus (Figure 2). During all four years of PAIVED, we enrolled 15,449 participants, among whom 188 episodes of influenza have been identified so far (1.2%). Table 1.PAIVED summary over four seasonsTable 2.Demographic characteristics of PAIVED participants during four seasonsFigure 2.Pathogens identified in ILI swabs collected in PAIVED (2021/22 season still in progress) Conclusion The fourth year of PAIVED was characterized by early (pre-enrollment) spread of influenza in some areas, as well the nationwide spread of the SARS-CoV-2 Omicron variant in December. As the swabs are processed and participants’ military health records are reviewed, we expect to identify more influenza cases; however, transmission patterns were far lower than historical averages due to pandemic precautions, making this surveillance data from identified strains more valuable. Comparative influenza vaccine effectiveness calculations will be performed to inform future vaccine purchasing decisions and we will compare serological response to the different vaccines. Disclosures Timothy Burgess, MD, MPH, AstraZeneca: The HJF, in support of the USU IDCRP, was funded to conduct or augment unrelated Phase III Mab and vaccine trials as part of US Govt. COVID19 response Jitendrakumar Modi, MD, GlaxoSmithKline: I am a paid speaker for GSK. I do not speak for their flu brand.
Published: 2022
Full Text: View/download PDF

36. 2064. Incidence and Risk Factors for Microscopic Hematuria in a US Military HIV Cohort

Author: Stephanie Wachs, Xiaohe Xu, Colton Daniels, Thankam Sunil, Kalyani Telu, Rhonda E Colombo, Tahaniyat Lalani, Catherine M Berjohn, Anuradha Ganesan, Brian Agan, Jason F Okulicz, and David A Lindholm
Subjects: Infectious Diseases, Oncology
Abstract: Background Microscopic hematuria (MH) is a common finding on screening urinalyses in persons living with HIV (PLWH); however, a study in the pre-HAART era revealed that a complete urologic evaluation was generally non-diagnostic in young males with a benign history and normal renal function. Recent studies have shown a decreased incidence of hematuria in PLWH in the HAART era. We performed a nested case-control study in the prospectively enrolled US Military HIV Natural History Study (NHS) to evaluate characteristics of PLWH with and without MH. Methods We evaluated male participants diagnosed with HIV and enrolled in the NHS Jan 2007 to Dec 2019. MH cases were defined as having at least one urinalysis with ≥5 RBCs/hpf. We used descriptive statistics to compare cases and controls with respect to demographics, comorbidities, and laboratory findings to determine risk factors for MH. Cox regression models evaluated for independent associations with the development of MH since HIV diagnosis. Results Of 829 included participants, 142 (17.1%) had MH, of whom 87 (61.3%) had only one MH event. Cases had a shorter mean duration of study follow-up but more analyzable urinalyses per participant. There were no significant differences between cases and controls in demographics, CD4 count nadir, time from HIV diagnosis to HAART initiation, or inclusion of tenofovir disoproxil fumarate (TDF) in initial regimen. On univariate analysis, more cases had a history of urinary tract infection (UTI) or a hypertension diagnosis through the time of incident MH compared to controls, but were less likely to have proteinuria or pyuria at the time of MH. Cox regression models revealed that a history of UTI increased the hazard for MH (HR 2.07, p < 0.05). In contrast, the presence of proteinuria (HR 0.42, p< 0.01) and TDF use (HR 0.56, p< 0.05) decreased the hazard for MH compared to controls. Conclusion A history of UTI, though not concurrent pyuria, was associated with an increased hazard for MH. The use of TDF in the initial HAART regimen and the presence of proteinuria were protective against hematuria. Future studies are needed to clarify these findings; however, they provide reassurance that in a young, otherwise healthy cohort, MH is typically self-limited and unrelated to intrinsic renal pathology, comorbidity, or HIV-related factor. Disclosures All Authors: No reported disclosures.
Published: 2022
Full Text: View/download PDF

37. 1392. Associations between Stigma and Physical and Mental Health in the U.S. Military HIV Natural History Study

Author: Natasha Schvey, Hsing-Chuan Hsieh, Luca Illinik, Xiuping Chu, Anuradha Ganesan, Christina Schofield, Rhonda E Colombo, Catherine M Berjohn, Jason Okulicz, and Brian Agan
Subjects: Infectious Diseases, Oncology
Abstract: Background Despite increasing attention to HIV-related stigma within the DoD, to date, the majority of research has focused on civilians, up to half of whom report perceived or experienced stigma. However, military service members and retirees with HIV may be particularly vulnerable to stigma and its adverse correlates. Methods The current study utilized cross-sectional data collected within the U.S. Military HIV Natural History Study. Participants completed questionnaires, including the Center for Epidemiologic Studies Depression scale, the Short Form Health Survey, the Internalization Subscale of the HIV Stigma Scale, and a measure of stigma experienced in the past year. Experiences of stigma were dichotomized to indicate presence or absence. Linear and logistic regressions were used to examine associations between internalized stigma and psychosocial functioning. All analyses were adjusted for age, race, sex, marital status, military rank, and duty status (i.e., active duty or retired). Results The sample comprised 399 participants (93.5% male; 46.0% Black/African American; Mage: 50.8 ± 13.2 years; Mage at HIV diagnosis: 31.9 ± 8.2 years; 32.4% on active duty). The majority (94.4%) had an undetectable viral load at the time of the visit. Fourteen percent reported being teased, treated unfairly, or discriminated against in the past year due to their HIV status, and 8% reported discrimination specifically within healthcare. Adjusting for covariates, internalized stigma was associated with poor physical (p < .001) and overall mental (p < .001) health. Internalized stigma was also associated with greater odds of reporting elevated depression (p < .001). Conclusion In this sample of service members and retirees with HIV, a small but significant minority of participants reported experiencing stigma. Rates of stigma were lower than those observed in some civilian samples, though heterogeneity in sampling and methodology preclude direct comparisons. Internalized stigma was associated with poor physical and mental health, signaling a need for continued efforts to assess both experienced and internalized stigma. Future research should explore associations between stigma, ART adherence, and other metrics of health, such as CD4 count, substance use, and cardiometabolic risk. Disclosures All Authors: No reported disclosures.
Published: 2022
Full Text: View/download PDF

38. 2200. Impact of COVID-19 Pandemic on Influenza-like Illness (ILI) Experience among Healthcare Workers in Military Treatment Facilities

Author: Ryan Liberg, Christina Schofield, Stephanie A Richard, Limone Collins, Christina Spooner, Srihari Seshadri, Anuradha Ganesan, Wesley R Campbell, David Hrncir, Tahaniyat Lalani, Tyler Warkentien, Katrin Mende, Ana E Markelz, Catherine M Berjohn, Bruce McClenathan, Jitendrakumar Modi, Alan Williams, Timothy Burgess, and Rhonda E Colombo
Subjects: Infectious Diseases, Oncology
Abstract: Background Healthcare workers (HCWs) are at heightened risk of exposure to respiratory pathogens, and occupy an important epidemiologic position in the COVID-19 pandemic. PAIVED, a multicenter, multiservice study assessing influenza vaccine effectiveness in the Department of Defense over four consecutive influenza seasons (2018-22), provides an opportunity to describe influenza like illness (ILI) experience and assess the impact of SARS-CoV-2 in HCWs compared to non-HCWs. Methods PAIVED participants were randomized to receive either egg-based, cell-based, or recombinant-derived influenza vaccine and then surveyed weekly for ILI. At enrollment, participants provided key demographic data including whether they were HCWs with direct patient contact. ILI was defined a priori as 1) having cough or sore throat plus 2) feeling feverish/having chills or having body aches/fatigue. Participants with ILI completed a symptom diary for seven days and submitted a nasal swab for pathogen detection. Study recruitment was conducted from September-January over four consecutive years. Results Of 13188 eligible participants enrolled, 4819 (36%) were HCWs. Overall, HCWs were more likely to be female (43% vs 31%), active duty military (86% vs 69%), and to identify as white (61% vs 56%). HCWs more commonly reported ILI than non-HCWs (25% vs 21%, p< 0.01). Of those experiencing ILI, SARS-CoV-2 was identified in a higher proportion of HCWs than non-HCWs (17% vs 12%, p< 0.01). Influenza was isolated in similar proportion of HCWs and non-HCWs (5% vs 4%). Each group reported similar ILI duration and severity (p< 0.01). Conclusion In a prior analysis of the 2019-20 PAIVED season, HCWs were more likely than non-HCWs to report ILI, have shorter illness duration, and isolate influenza A (H1N1). The propensity for HCWs to report ILI persisted over the four years. While SARS-CoV-2 emerged as a major pathogen in both groups, HCWs were more likely to have it identified as a cause of ILI, suggesting increased risk of symptomatic SARS-CoV-2 in our HCW population. Influenza incidence was lower than that of SARS-COV-2, and did not differ between HCWs and non-HCWs. Mean duration of illness did not differ between groups over four years; this equalization may relate to the higher incidence of SARS-CoV-2 in HCWs. Disclosures Jitendrakumar Modi, MD, GlaxoSmithKline: I am a paid speaker for GSK. I do not speak for their flu brand. Timothy Burgess, MD, MPH, AstraZeneca: The HJF, in support of the USU IDCRP, was funded to conduct or augment unrelated Phase III Mab and vaccine trials as part of US Govt. COVID19 response.
Published: 2022
Full Text: View/download PDF

39. An Assessment of Nighttime Electrofishing in the Lower Wabash River

Author: Anabela Maia, Scott J. Meiners, Cassi J. Moody-Carpenter, Eric C. Hine, and Robert E. Colombo
Subjects: Hydrology, Ecology, Electrofishing, Environmental science, Management, Monitoring, Policy and Law, Aquatic Science, Ecology, Evolution, Behavior and Systematics
Published: 2021
Full Text: View/download PDF

40. MAGIC and Fermi-LAT gamma-ray results on unassociated HAWC sources

Author: M. L. Ahnen, S. Ansoldi, L. A. Antonelli, C. Arcaro, D. Baack, A. Babic, B. Banerjee, P. Bangale, U. Barres de Almeida, J. A. Barrio, J. Becerra Gonzalez, W. Bednarek, E. Bernardini, R. Ch. Berse, A. Berti, W. Bhattacharyya, A. Biland, O. Blanch, G. Bonnoli, R. Carosi, A. Carosi, G. Ceribella, A. Chatterjee, S. M. Colak, P. Colin, E. Colombo, J. L. Contreras, J. Cortina, S. Covino, P. Cumani, P. Da Vela, F. Dazzi, A. De Angelis, B. De Lotto, M. Delfino, J. Delgado, F. Di Pierro, A. Domınguez, D. Dominis Prester, D. Dorner, M. Doro, S. Einecke, D. Elsaesser, V. Fallah Ramazani, A. Fernandez-Barral, D. Fidalgo, M. V. Fonseca, L. Font, C. Fruck, D. Galindo, R. J. Garcıa Lopez, M. Garczarczyk, M. Gaug, P. Giammaria, N. Godinovic, D. Gora, D. Guberman, D. Hadasch, A. Hahn, T. Hassan, M. Hayashida, J. Herrera, J. Hose, D. Hrupec, K. Ishio, Y. Konno, H. Kubo, J. Kushida, D. Kuvezdic, D. Lelas, E. Lindfors, S. Lombardi, F. Longo, M. Lopez, C. Maggio, P. Majumdar, M. Makariev, G. Maneva, M. Manganaro, K. Mannheim, L. Maraschi, M. Mariotti, M. Martınez, S. Masuda, D. Mazin, K. Mielke, M. Minev, J. M. Miranda, R. Mirzoyan, A. Moralejo, V. Moreno, E. Moretti, T. Nagayoshi, V. Neustroev, A. Niedzwiecki, M. Nievas Rosillo, C. Nigro, K. Nilsson, D. Ninci, K. Nishijima, K. Noda, L. Nogues, S. Paiano, J. Palacio, D. Paneque, R. Paoletti, J. M. Paredes, G. Pedaletti, M. Peresano, M. Persic, P. G. Prada Moroni, E. Prandini, I. Puljak, J. R. Garcia, I. Reichardt, W. Rhodes, M. Ribo, J. Rico, C. Righi, A. Rugliancich, T. Saito, K. Satalecka, T. Schweizer, J. Sitarek, I. Snidaric, D. Sobczynska, A. Stamerra, M. Strzys, T. Suric, M. Takahashi, L. Takalo, F. Tavecchio, P. Temnikov, T. Terzic, M. Teshima, N. Torres-Alba, A. Treves, S. Tsujimoto, G. Vanzo, M. Vazquez Acosta, I. Vovk, J. E. Ward, M. Will, D. Zaric, A. Albert, R. Alfaro, C. Alvarez, R. Arceo, J. C. Arteaga-Velazquez, D. Avila Rojas, H. A. Ayala Solares, A. Becerril, E. Belmont-Moreno, S. Y. BenZvi, A. Bernal, J. Braun, K. S. Caballero-Mora, T. Capistran, A. Carraminana, S. Casanova, M. Castillo, U. Cotti, J. Cotzomi, S. Coutino de Leon, C. De Leon, E. De la Fuente, R. Diaz Hernandez, S. Dichiara, B. L. Dingus, M. A. DuVernois, J. C. Dıaz-Velez, R. W. Ellsworth, K. Engel, O. Enriquez-Rivera, D. W. Fiorino, H. Fleischhack, N. Fraija, J. A. Garcıa-Gonzalez, F. Garfias, A. Gonzalez-Munoz, M. M. Gonzalez, J. A. Goodman, Z. Hampel-Arias, J. P. Harding, S. Hernandez, F. Hueyotl-Zahuantitla, C. M. Hui, P. Huntemeyer, A. Iriarte, A. Jardin-Blicq, V. Joshi, S. Kaufmann, A. Lara, R. J. Lauer, W. H. Lee, D. Lennarz, H. Leon Vargas, J. T. Linnemann, A. L. Longinotti, G. Luis-Raya, R. Luna-Garcıa, R. Lopez-Coto, K. Malone, S. S. Marinelli, O. Martinez, I. Martinez-Castellanos, J. Martınez-Castro, H. Martınez-Huerta, J. A. Matthews, P. Miranda-Romagnoli, E. Moreno, A. Nayerhoda, L. Nellen, M. Newbold, M. U. Nisa, R. Noriega-Papaqui, R. Pelayo, J. Pretz, E. G. Perez-Perez, Z. Ren, C. D. Rho, C. Riviere, D. Rosa-Gonzalez, M. Rosenberg, E. Ruiz-Velasco, F. Salesa Greus, A. Sandoval, M. Schneider, M. Seglar Arroyo, G. Sinnis, A. J. Smith, R. W. Springer, P. Surajbali, I. Taboada, O. Tibolla, K. Tollefson, I. Torres, T. N. Ukwatta, G. Vianello, L. Villasenor, F. Werner, S. Westerhoff, J. Wood, T. Yapici, G. Yodh, A. Zepeda, H. Zhou, J. D. Alvarez, M. Ajello, L. Baldini, G. Barbiellini, B. Berenji, E. Bissaldi, R. D. Blandford, R. Bonino, E. Bottacini, T. J. Brandt, J. Bregeon, P. Bruel, R. A. Cameron, R. Caputo, P. A. Caraveo, D. Castro, E. Cavazzuti, G. Chiaro, S. Ciprini, D. Costantin, F. D'Ammando, F. de Palma, A. Desai, N. Di Lalla, M. Di Mauro, L. Di Venere, C. Favuzzi, Y. Fukazawa, S. Funk, P. Fusco, F. Gargano, D. Gasparrini, N. Giglietto, F. Giordano, M. Giroletti, T. Glanzman, D. Green, I. A. Grenier, S. Guiriec, A. K. Harding, E. Hays, J. W. Hewitt, D. Horan, G. Johannesson, M. Kuss, S. Larsson, I. Liodakis, F. Loparco, P. Lubrano, J. D. Magill, S. Maldera, A. Manfreda, M. N. Mazziotta, I. Mereu, P. F. Michelson, T. Mizuno, M. E. Monzani, A. Morselli, I. V. Moskalenko, M. Negro, E. Nuss, N. Omodei, M. Orienti, E. Orlando, J. F. Ormes, M. Palatiello, V. S. Paliya, M. Pesce-Rollins, V. Petrosian, F. Piron, T. A. Porter, G. Principe, S. Raino, B. Rani, M. Razzano, S. Razzaque, A. Reimer, O. Reimer, C. Sgro, E. J. Siskind, G. Spandre, P. Spinelli, H. Tajima, J. B. Thayer, David J Thompson, D. F. Torres, E. Torresi, E. Troja, J. Valverde, K. Wood, and M. Yassine
Subjects: Astronomy, Astrophysics
Abstract: The HAWC Collaboration released the 2HWC catalogue of TeV sources, in which 19 show no association with any known high-energy (HE; E ≳ 10 GeV) or very-high-energy (VHE; E ≳ 300 GeV) sources. This catalogue motivated follow-up studies by both the Major Atmospheric Gamma-ray Imaging Cherenkov (MAGIC) and Fermi-LAT (Large Area Telescope) observatories with the aim of investigating gamma-ray emission over a broad energy band. In this paper, we report the results from the first joint work between High Altitude Water Cherenkov (HAWC), MAGIC, and Fermi-LAT on three unassociated HAWC sources: 2HWC J2006+341, 2HWC J1907+084*, and 2HWC J1852+013*. Although no significant detection was found in the HE and VHE regimes, this investigation shows that a minimum 1° extension (at 95 per cent confidence level) and harder spectrum in the GeV than the one extrapolated from HAWC results are required in the case of 2HWC J1852+013*, whilst a simply minimum extension of 0.16° (at 95 per cent confidence level) can already explain the scenario proposed by HAWC for the remaining sources. Moreover, the hypothesis that these sources are pulsar wind nebulae is also investigated in detail.
Published: 2019
Full Text: View/download PDF

41. Influenza Vaccine Effectiveness: Analysis of the Impact of Repeated Vaccinations in Military Health System Beneficiaries

Author: Stephanie A Richard, Mary Fairchok, Christian Coles, Timothy H Burgess, and Rhonda E Colombo
Subjects: Infectious Diseases, Oncology
Abstract: Background Influenza has long burdened the Military Health System (MHS). This study assesses the impact of repeated annual vaccination on influenza vaccine effectiveness (VE). Methods This retrospective, case control study using the test-negative design utilized data extracted from the MHS Data Repository (MDR). Cases had a positive influenza test and controls sought care for an influenza-like illness within 2 weeks of a case, had no positive influenza tests, and were matched by sex, race, age, and location. Vaccine effectiveness was assessed using conditional logistic regression separately for those who received inactivated and live attenuated influenza vaccines (LAIV). Results A total of 6860 cases and controls were identified in the MDR, among whom 53% were vaccinated in all 3 seasons. Among those who received inactivated influenza vaccine during the current season, VE ranged from 26% to 37% (2012/13 [A(H3N2)]: VE 26%, 95% confidence interval [CI] = 1%–45%; 2013/14 [A(H1N1)pdm09]: VE 37%, 95% CI = 18%–52%; 2014/15 [A(H3N2)]: VE 31%, 95% CI = 17%–42%). The VE ranged from 25% to 49% for those only vaccinated this season (2012/13 [A(H3N2)]: VE 38%, 95% CI = −3% to 63%; 2013/14 [A(H1N1)pdm09]: VE 49%, 95% CI = 11%–71%; 2014/15 [A(H3N2)]: VE 25%, 95% CI = −7% to 48%). The VE was more variable in those who received LAIV in the current season. No statistically significant differences in VE were observed between those frequently vaccinated and those vaccinated only during the current season. Conclusions These results underscore the value of annual influenza vaccinations for preventing infection while highlighting the need for continued improvements in influenza vaccine effectiveness.
Published: 2022
Full Text: View/download PDF

42. Effects of Human Immunodeficiency Virus Status on Symptom Severity in Influenza-Like Illness in An Otherwise Healthy Adult Outpatient Cohort

Author: John C. Arnold, Eugene V. Millar, Rhonda E Colombo, Michelande Ridore, Anuradha Ganesan, Ryan C. Maves, Tahaniyat Lalani, Stephanie A Richard, Patrick Danaher, Timothy Burgess, Christian L. Coles, Brian K. Agan, Wei-Ju Chen, Christina Schofield, and Mary P. Fairchok
Subjects: Adult, Male, 0301 basic medicine, medicine.medical_specialty, HIV Positivity, 030106 microbiology, HIV Infections, medicine.disease_cause, Antiviral Agents, General Biochemistry, Genetics and Molecular Biology, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Influenza, Human, Outpatients, Pandemic, medicine, Humans, 030212 general & internal medicine, acute disease, Original Research, Influenza-like illness, Picornaviridae Infections, business.industry, Confounding, virus diseases, General Medicine, respiratory tract diseases, Diarrhea, Cohort, medicine.symptom, Rhinovirus, business, Cohort study
Abstract: The impact of HIV on influenza-like illness (ILI) has been incompletely described in the era of combination antiretroviral therapy, particularly in the post-H1N1 pandemic period. This analysis informs on ILI in an otherwise healthy, predominantly outpatient cohort of adults with HIV in the USA. From September 2010 to March 2015, this multisite observational cohort study enrolled otherwise healthy adults presenting to a participating US military medical center with ILI, a subset of whom were HIV positive. Demographics, clinical data, and self-reported symptom severity were ascertained, and enrollees completed a daily symptom diary for up to 10 days. 510 men were included in the analysis; 50 (9.8%) were HIV positive. Subjects with HIV were older and less likely to be on active duty. Rhinovirus and influenza A were the most commonly identified pathogens. Moderate-severe diarrhea (p
Published: 2021
Full Text: View/download PDF

43. Clinical, Immunological, and Virological SARS-CoV-2 Phenotypes in Obese and Nonobese Military Health System Beneficiaries

Author: Stephanie A Richard, David A Lindholm, Nusrat J. Epsi, Caroline English, Nikhil Huprikar, Mark P Simons, Timothy Burgess, Anthony C. Fries, Cristian Madar, Christopher J Colombo, Ryan C. Maves, Anuradha Ganesan, Simon Pollett, Rhonda E Colombo, Eric D Laing, David R. Tribble, Eugene V. Millar, Katrin Mende, Sharon Chi, Tahaniyat Lalani, Christopher C. Broder, Brian K. Agan, and Derek T Larson
Subjects: medicine.medical_specialty, business.industry, medicine.medical_treatment, Odds ratio, Anthropometry, Logistic regression, medicine.disease, Obesity, Confidence interval, Infectious Diseases, Oxygen therapy, Internal medicine, medicine, Immunology and Allergy, business, Body mass index, Viral load
Abstract: Background The mechanisms underlying the association between obesity and coronavirus disease 2019 (COVID-19) severity remain unclear. After verifying that obesity was a correlate of severe COVID-19 in US Military Health System (MHS) beneficiaries, we compared immunological and virological phenotypes of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in both obese and nonobese participants. Methods COVID-19–infected MHS beneficiaries were enrolled, and anthropometric, clinical, and demographic data were collected. We compared the SARS-CoV-2 peak IgG humoral response and reverse-transcription polymerase chain reaction viral load in obese and nonobese patients, stratified by hospitalization, utilizing logistic regression models. Results Data from 511 COVID-19 patients were analyzed, among whom 24% were obese and 14% severely obese. Obesity was independently associated with hospitalization (adjusted odds ratio [aOR], 1.91; 95% confidence interval [CI], 1.15–3.18) and need for oxygen therapy (aOR, 3.39; 95% CI, 1.61–7.11). In outpatients, severely obese had a log10 (1.89) higher nucleocapsid (N1) genome equivalents (GE)/reaction and log10 (2.62) higher N2 GE/reaction than nonobese (P = 0.03 and P < .001, respectively). We noted a correlation between body mass index and peak anti-spike protein IgG in inpatients and outpatients (coefficient = 5.48, P < .001). Conclusions Obesity is a strong correlate of COVID-19 severity in MHS beneficiaries. These findings offer new pathophysiological insights into the relationship between obesity and COVID-19 severity.
Published: 2021
Full Text: View/download PDF

44. Bigheaded Carp Spatial Reproductive Dynamics in Illinois and Wabash River Tributaries

Author: Eden L. Effert-Fanta, Cassi J. Moody-Carpenter, Kellie N. Hanser, Samuel J. Schaick, Robert E. Colombo, and Daniel R. Roth
Subjects: Fishery, geography, geography.geographical_feature_category, Ecology, biology, Tributary, Management, Monitoring, Policy and Law, Aquatic Science, Carp, biology.organism_classification, Ecology, Evolution, Behavior and Systematics
Published: 2021
Full Text: View/download PDF

45. Impact assessment of innovation tax incentives in Brazil

Author: Daniel Gama e Colombo and Hélio Nogueira da Cruz
Subjects: Net profit, Organizational Behavior and Human Resource Management, Public economics, Impact assessment, 05 social sciences, Beneficiary, Test (assessment), Incentive, Empirical research, Management of Technology and Innovation, Microdata (HTML), 0502 economics and business, Propensity score matching, Business, Management and Accounting (miscellaneous), 050211 marketing, Business, Business and International Management, 050203 business & management
Abstract: PurposeThis paper evaluates the effects of tax incentives on business innovation in Brazil that were established by Law 11,196/05 (the “Fiscal Incentives Law”) to test whether they have had a positive impact on beneficiary firms' innovation input and output and on their performance.Design/methodology/approachThe policy impacts are estimated using microdata on 13,706 firms available in the 2008 and 2011 editions of the Brazilian Innovation Survey (PINTEC) and by applying propensity score matching with difference-in-differences.FindingsThe results suggest a positive and statistically significant impact of the policy on research and development (R&D) expenditures (average of approximately US$ 264,000 in 2011), the number of research staff (average of five researchers) and total employment (approximately 5% of the beneficiary firms' mean size). However, no impact was found on the overall spending on innovative activities, the percentage of sales and exports from new products, net revenue or net revenue per employee.Practical implicationsThe findings provide empirical support in favor of tax incentives as a policy tool to boost business innovation in the country. However, the absence of significant effects on innovative activities expenditures and on most indicators of innovation output and firms' performance reveals shortcomings of the policy that need to be addressed.Originality/valueThe study complements and advances the findings of previous studies by assessing policy impact on total innovative activities expenditures and on innovation output and firm performance.
Published: 2021
Full Text: View/download PDF

46. The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA Vaccine-Breakthrough Infection Phenotype Includes Significant Symptoms, Live Virus Shedding, and Viral Genetic Diversity

Author: Timothy Burgess, Darci R. Smith, Anthony C. Fries, Anuradha Ganesan, Eric D Laing, Derek T Larson, Brian K. Agan, Emily C Samuels, Tahaniyat Lalani, Cristian Madar, Christopher J Colombo, Rupal M. Mody, Stephanie A Richard, Katrin Mende, Mark P Simons, David R. Tribble, Tida Lee, Sharon Chi, Christopher C. Broder, Rhonda E Colombo, and Simon Pollett
Subjects: Microbiology (medical), 2019-20 coronavirus outbreak, COVID-19 Vaccines, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), 030204 cardiovascular system & hematology, 03 medical and health sciences, 0302 clinical medicine, Genotype, Humans, Medicine, RNA, Messenger, 030212 general & internal medicine, Live virus, Vaccines, Synthetic, Messenger RNA, Genetic diversity, SARS-CoV-2, business.industry, COVID-19, Genetic Variation, Breakthrough infection, Virology, Phenotype, Virus Shedding, Infectious Diseases, mRNA Vaccines, business
Abstract: Little is known about severe acute respiratory syndrome coronavirus 2 “vaccine-breakthrough” infections (VBIs). Here we characterize 24 VBIs in predominantly young healthy persons. While none required hospitalization, a proportion endorsed severe symptoms and shed live virus as high as 4.13 × 103 plaque-forming units/mL. Infecting genotypes included both variant-of-concern (VOC) and non-VOC strains.
Published: 2021
Full Text: View/download PDF

47. Comparison of Active and Passive Larval Sampling Gears in Monitoring Reproduction of Invasive Bigheaded Carps in Large‐River Tributaries

Author: Eden L. Effert-Fanta, David H. Wahl, Robert E. Colombo, Daniel R. Roth, and Jordan Pesik
Subjects: Larva, geography, geography.geographical_feature_category, Ecology, media_common.quotation_subject, Sampling (statistics), Management, Monitoring, Policy and Law, Aquatic Science, Biology, Fishery, Tributary, Reproduction, Ecology, Evolution, Behavior and Systematics, media_common
Published: 2021
Full Text: View/download PDF

48. Comparison of Four Hard Structures Including Otoliths for Estimating Age in Blue Suckers

Author: Alec R. Lackmann, Dakota S. Radford, Cassi J. Moody-Carpenter, and Robert E. Colombo
Subjects: Geography, Aquatic Science, Ecology, Evolution, Behavior and Systematics
Published: 2021
Full Text: View/download PDF

49. The Role of Tax Incentives in Innovation Policies: theoretical considerations and recent developments

Author: Daniel Gama e Colombo
Subjects: General Medicine
Abstract: The objective of this paper is to discuss the role of tax incentives as part of national innovation policies from a theoretical perspective. Tax incentives are commonly interpreted as closer to a market failure rationale, but they can also play a role as part of a broad evolutionary policy strategy. The theoretical debate provides a conceptual framework to explain the increasing relevance of tax incentives in different countries as from the 2008 economic crisis. The Brazilian experience seems inconsistent with this trend, as the reduction of public budget to innovation was not followed by an upsurge of tax incentives.
Published: 2022
Full Text: View/download PDF

50. Post-vaccination Omicron infections induce broader immunity across antigenic space than prototype mRNA COVID-19 booster vaccination or primary infection

Author: Wei Wang, Sabrina Lusvarghi, Rahul Subramanian, Nusrat J. Epsi, Richard Wang, Emilie Goguet, Anthony C Fries, Fernando Echegaray, Russell Vassell, Si’Ana Coggins, Stephanie A. Richard, David A. Lindholm, Katrin Mende, Evan Ewers, Derek Larson, Rhonda E. Colombo, Christopher Colombo, Janet O. Joseph, Julia Rozman, Alfred Smith, Tahaniyat Lalani, Catherine Berjohn, Ryan Maves, Milissa Jones, Rupal Mody, Nikhil Huprikar, Jeffrey Livezey, David Saunders, Monique Hollis-Perry, Gregory Wang, Anuradha Ganesan, Mark P. Simons, Christopher C. Broder, David Tribble, Eric D. Laing, Brian Agan, Timothy H. Burgess, Edward Mitre, Simon D. Pollett, Leah C. Katzelnick, and Carol D. Weiss
Abstract: SummaryThe rapid emergence of new SARS-CoV-2 variants challenges vaccination strategies. Here, we measured antigenic diversity among variants and interpreted neutralizing antibody responses following single and multiple exposures in longitudinal infection and vaccine cohorts. Antigenic cartography using primary infection antisera showed that BA.2, BA.4/BA.5, and BA.2.12.1 are distinct from BA.1 and closer to the Beta cluster. Three doses of an mRNA COVID-19 vaccine increased breadth to BA.1 more than to BA.4/BA.5 or BA.2.12.1. Omicron BA.1 post-vaccination infection elicited antibody landscapes characterized by broader immunity across antigenic space than three doses alone, although with less breadth than expected to BA.2.12.1 and BA.4/BA.5. Those with Omicron BA.1 infection after two or three vaccinations had similar neutralizing titer magnitude and antigenic breadth. Accounting for antigenic differences among variants of concern when interpreting neutralizing antibody titers aids understanding of complex patterns in humoral immunity and informs selection of future COVID-19 vaccine strains.
Published: 2022
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Category

Publication Type

Journal

Region

Database

Publisher

1,184 results on '"E. Colombo"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources